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CHAPTER 1 
INTRODUCTION 
Malignant cells commonly exhibit increased activity 
of several degradative enzymes that are believed to 
contribute to their invasive and metastatic potential. Of 
special interest in this regard are proteases such as 
cathepsin B and L, and urine-type plasminogen activator 
(uPA). However, little is known about the pattern of 
protease gene expressions caused by different oncogene 
transformation. 
Non-transformed NIH 3T3 and NIH 3T3 murine 
fibroblasts transfected with 4 different ras oncogene 
constructs have been characterized with respect to their 
metastatic potential in nude mice. The PC3-P and PC3-M cell 
lines are human prostate carcinoma cell lines with a 
different metastatic potential. A375-P & A375-M cells lines 
are derived from a human melanoma with a different 
metastatic potential. 
Tumor promoting phorbol esters such as phorbol-12-
myristate-13-acetate (PMA) are diacylglycerol (DAG) analogs 
which directly stimulate the phospholipid-dependent protein 
kinase C (PKC). Studies on the effects of the potent tumor 
promoter (PMA) have demonstrated that it induces a highly 
2 
pleiotropic response in a variety of cell lines, including a 
more metastatic phenotype, and increased expression of 
several different proteases and protease inhibitors. 
However, it is not known whether the cellular response to 
phorbol esters differs among tumor cells with different 
oncogene transformation and metastatic potentials. There 
were three specific aims of this project: 
(1) To explore the mechanism by which oncogenes 
induce the metastatic phenotype by studying protease gene 
induction and regulation by ras oncogenes. 
(2) To determine how exogenous signal factors 
regulate protease and protease inhibitor expressions in 
transformed and metastastic cells. 
The results of this project may contribute to the 
understanding of the complexity of proteases expression and 
involvement in tumor metastasis. 
Chapter II 
REVIEW OF THE LITERATURE 
Tumor Metastasis and Proteases 
Malignant tumors differ from benign tumors in their 
ability to spread throughout the body, giving rise to 
metastases at sites distant from the primary tumor. 
Metastasis is a complex process involving many steps, each 
has its own regulatory mechanism (Foste, G. and Fidler, J. 
J., 1980). However, from a simple point of view, the 
following types of invasive and degradative processes must 
occur in order for a secondary tumor to be established. A 
cell must break away from the primary tumor mass, penetrate 
the tissues surrounding the tumor, and move through the 
cellular layers and basement membrane of blood and lymph 
vessels in order to enter the circulatory system. Tumor 
cells are then disseminated by the blood and lymphatic 
circulation. Subsequently, they must extravasate from the 
circulation and reach a site favorable for proliferation. 
The result of the process is the formation of a new tumor. 
It has been recognized for many years that a positive 
3 
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correlation exists between cellular invasion and proteinase 
production, and it has been hypothesized that proteolytic 
activity may, in fact, be required for invasiveness. 
According to this theory, cells are invasive by virtue of 
their ability to secrete (or induce secretion of) 
proteinases capable of degrading the molecules which compose 
the barriers they must cross. These barriers include 
basement membrane, interstitial tissue and extracellular 
matrices, which are composed primarily of collagen, 
proteoglycan, elastin and other glycoproteins. 
Considerable evidence has amassed suggesting that a 
number of proteinases capable of degrading the molecular 
barriers are associated with transformed cells. The best 
characterized or identified enzymes are urokinase-type 
plasminogen activator (uPA), type IV collagenases, 
stromelysin, and cathepsin B-like and cathepsin L-like 
proteinases. 
Biochemistry of Plasminogen Activators 
One of the most studied wide-spectrum proteinase is 
the serine protease plasmin. Plasmin is able to dissolve 
fibrin clots, digest extracellular matrix proteins, and 
activate latent enzymes and hormones (Mullins and Rohrlich, 
1983). It is formed by the proteolytic cleavage of the 
abundant proenzyme plasminogen. Plasminogen is a 791 amino 
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acid zymogen which is activated to the broad-specificity 
protease plasmin by a single proteolytic cleavage at Arg-
560. The reaction is mainly catalyzed by two molecularly 
different, functionally similar, enzymes called plasminogen 
activators (PAs), urokinase-type plasminogen activator (uPA) 
and tissue-type plasminogen activator (t-PA). Both are 
widely distributed in body fluids and tissues, but uPA is 
more abundant in urine while t-PA is more abundant in plasma 
(Blasi, et al., 1987). They participate in the regulation of 
several physiological processes by initiating a reaction 
leading to the formation of active plasmin. t-PA is regarded 
as an important mediator of the fibrinolytic activity in 
circulation. u-PA has a role in cellular invasion and 
tissue involution (Beer et al., 1975), cellular migratory 
activity (Vassalli, et al., 1976), trophoblast implantation 
(Strickland et al., 1976), and mammary gland involution 
(Ossowski et al., 1979), tumor invasion and metastasis 
(Ossowski and Reich, 1983), and a variety of other 
physiological processes. 
Structure and Regulation of uPA 
The primary structure of uPA has been determined both 
by protein sequencing and by deducing the amino acid 
sequence from its cloned cDNA. The human uPA is the 
translated, active and mature product of a 2.5 kb-long mRNA, 
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(Verde et al., 1984) which is transcribed from a 6.5 kb gene 
present on the long arm of chromosome 10 (Tripputi et al., 
1985). It is organized in 11 exons and 10 introns (Riccio et 
al., 1985). Translation of the mRNA yields a prepro-uPA with 
431 amino and with a molecular weight 54 kD. Removal of a 20 
residue long signal peptide gives rise to the secreted 
single-chain pro-uPA, which is a glycosylated polypeptide 
(in human) of about 50 kD (Pennica et al., 1983). Mouse u-
PA, however, contains no N-glycosylation site (Belin et al., 
1985). It is this pro-uPA that is released from a variety of 
cultured normal and neoplastic cell types, and appears to be 
the predominant extracellular form of u-PA in the organism 
(Dano, et al., 1985). The single-chain uPA is considered a 
proenzyme form that has little or no proteolytic activity 
against the natural substrate plasminogen, and no activity 
against synthetic plasminogen activator substrates. Single-
chain uPA is converted into an active two chain form with Mr 
50,000 by proteolytic cleavage after lysine-158, resulting 
in two polypeptide chains held together by one disulfide 
bond (Guenzler et al., 1982) This conversion can be 
catalyzed by plasmin (Dano et al., 1985), plasma kallikrein 
(Ichinose et al., 1986), factor XIIa (Ichinose et al., 
1986), trypsin (Eaton et al., 1984), and thrombin (Easton et 
al., 1984) . 
The regulation of uPA production has been reported to 
be associated with various compounds such as growth factors 
7 
and the tumor promoter phorbol-12-myristate-13-acetate (PMA) 
(Degen et al., 1985; Collart et al., 1986; Bell et al., 
1990). It is increased by epidermal growth factor (EGF) 
(Boyd, 1989; Niedbala and Sartorelli, 1989), platelet-
derived growth factor (PDGF) (Stoppelli et al., 1986), 
interferon (INF-gamma) (Collart et al., 1986), transforming 
growth factor beta (Keski-Oja et al., 1988), vasopressin 
(Nagamine et al., 1983) and estrogen (Mira-y-Lopez et al., 
1983). Glucocorticoids have been shown to decrease uPA 
production in certain normal and malignant cells (Medcalf et 
al, 1986, Busso et al., 1987). 
uPA receptor 
Several types of cells possess specific high affinity 
(Kd = 10 -io M) plasma membrane binding sites for uPA. Human 
peripheral blood monocytes (Vassalli et al., 1985), the 
monocyte-like U937 cells, fibroblasts, and HT1080 
fibrosarcoma cells (Testa and Quigley, 1988) all have 
approximately 105 such specific receptors per cell. The 
receptor was shown to be a 55-60 kD glycoprotein (Nielsen et 
al., 1988). The region of u-PA that binds the receptor is 
located on the 135-residue-long amino terminal fragment 
(ATF) of the A-chain of two chain urokinase. More precisely, 
the first 32 residues of the "growth factor" region of the 
ATF peptide is required for receptor binding. The ATF 
8 
fragment comprises two structural domains, a "growth factor" 
region with homology to EGF and a kringle domain (Patthy L., 
1985}. In contrast, the Mr 33,000 KDa form of u-PA, a 
partial degradation product of the two chain Mr 50,000 
enzyme, lacks the ATF and does not interact with the 
receptor. The 33,000 dalton form, however, retains catalytic 
activity (Stoppelli et al., 1985). Receptor binding does not 
require u-PA catalytic activity, and the single-chain 
zymogen u-PA binds with about the same affinity as does the 
active Mr 50,000 two-chain enzyme. 
The receptor-bound forms of plasminogen activator is 
enzymatic active, and binding of either the one-chain and 
two-chain u-PA to the u-PA receptor on cultured human 
monocytes-macrophage results in the generation of plasmin-
mediated pericellular proteolysis (Dano et al., 1985). Thus 
the presence of a u-PA receptor allows cells to acquire 
surface-bound plasminogen-activating ability. 
Roles of uPA in Neoplasia 
The first experiment showing a direct cause-effect 
relationship between uPA and metastasis is that performed by 
Ossowski and Reich (Ossowski and Reich, 1983). They found 
that human HEp3 cells inoculated onto the chorio-allantoic 
membrane of a chicken embryo were able to metastasize to the 
lung of the embryo and that this process could be blocked by 
9 
specific anti-catalytic antibodies against human uPA. 
There are multiple reports of an increase in the 
synthesis of uPA in cultured cells transformed by oncogenes 
or oncogenic viruses, on treatment of cultured cells with 
tumor promoter, and on the assay of transformed tissue in 
comparison to surrounding normal tissues (reviewed by Dano 
et al., 1985). However there also are a number of reports 
showing a lack of correlation or a negative correlation 
between uPA activity and ability to metastasize (Harvey et 
al., 1988; Graf et al., 1984; Giraldi et al., 1985). 
Recently, more direct evidence in support of a role of 
urokinase in tumor cell metastasis has come from experiments 
in which the expression of the human urokinase sense and 
anti-sense genes expressed in murine B16 cells has been 
shown to increase or decrease the metastatic potential of 
these cells (Yu and Schultz, 1990). Also, the overexpression 
of human uPA increases the capacity of ras-transformed 
murine NIH 3T3 cells to colonize the nude mouse lung after 
tail-vein injection. (Axelrod et al., 1989). 
PA inhibitor 
Precise regulation of plasminogen activator (PA) 
activity constitutes a critical feature of many biological 
processes. This regulation may occur at various levels, 
including the synthesis and secretion of PAs, and the 
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interaction with specific PA inhibitors, the PAis {Sprengers 
and Kluft, 1987). The two most important protease inhibitors 
specific for PAs (PAI-1 and PAI-2) have recently been 
identified and characterized. 
Plasminogen activator inhibitor type 1 {PAI-1) is the 
major PAI found in plasma (Kruithof et al., 1983; Thorsen 
and Philips, 1984). It has been shown to be expressed in 
many body tissues (Quax et al., 1990; Erickson et al., 
1990), the conditioned media of fibrosarcoma cells 
(Andreason et al., 1986), hepatocytes {Sprengers et al., 
1985), smooth muscle (Laug, 1987) and melanoma cells (Wagner 
and Binder, 1986). It is a 50-kDa glycoprotein, belonging to 
the serpin family (Pannekoek et al., 1986; Ny et al., 1986), 
and a specific inhibitor of both tissue-type PA and 
urokinase-type PA (Kruithof et al., 1984; Kruithof et al., 
1986) . 
The biosynthesis of PAI-1 appears to be highly 
regulated. For example, PAI-1 synthesis can be induced by 
endotoxin {Culucci et al., 1985), inflammatory mediators 
(Emeis and Kooistra, 1986; Sawdey et al., 1989), 
glucocorticoid {Andreasen et al., 1987), insulin (Kooistra 
et al., 1989) and phorbol ester (Mayer et al., 1988). 
Plasminogen activator inhibitor type 2 {PAI-2) has 
been purified from the human placenta (Kawano et al., 1986) 
and epidermis {Astedt et al., 1986) It is produced by many 
cell types including monocyte-macrophage and human 
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histiocytic lymphoma cells (Kruithof et al., 1986). The cDNA 
cloning and amino acid sequence of PAI-2 have been 
determined from human placenta (Ye et al., 1987), human 
histiocytic lymphoma cells (Schleuning et al., 1987), and 
human monocyte (Wagner and Binder, 1987). PAI-2 consists of 
415 amino acids, corresponding to a Mr 47 kD protein. It 
exists in two forms, a 47 -kD, pl 5.0, nonglycosylated form 
and a 60-kd, pl 4.4, glycosylated form, with similar PA 
inhibition characteristics (Genton, et al., 1987; Wohlwend 
et al., 1987). Interestingly, in short-term culture, the 
nonglycosylated form, representing over 90% of synthesized 
PAI-2, is only found intracellularly, whereas the 
glycosylated form is secreted (Genton, et al., 1987; 
Wohlwend et al., 1987). 
The regulation of PAI-2 production in macrophage has 
been characterized in some detail. It is decreased by 
dexamethasone but increased by the tumor promoter phorbol 
myristate acetate (Kruithof et al., 1986; Schleuning, et 
al., 1987), endotoxin (Chapman and stone, 1985), and muramyl 
dipeptide (Stephens, et al., 1985). In peripheral blood 
mononuclear cells lipopolysaccharide increases the release 
of PAI-2 leading to an anti-f ibrinolytic state (Schwartz et 
al., 1988). 
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structure and Regulation of cathepsin B 
cathepsin B is one of most characterized cysteine 
proteinase. Cathepsin B has been purified from many 
different normal tissues of numerous species. Mature 
cathepsin B seems to exist in either a single chain form of 
39 kDa or a double chain form of 25 and 5 kDa. The 
proportions of the single and double chain forms varying 
from species to species. The active site of cathepsin B was 
found in the light or 5 kDa chain of the double chain form. 
The preprocathepsin B cDNAs have been isolated from 
rat (Segundo et al., 1986), mouse (Chan et al., 1986) and 
human (Chan et al., 1986). Based on the nucleotide sequence, 
cathepsin B is synthesized as a preproenzyme of 339 amino 
acids, which consists of a 17 residue prepeptide sequence at 
the N-terminus, a 62 residue propeptide sequence, and a 6 
residue extension at the carboxyl terminus. The signal 
peptide of 17 amino acids in preprocathepsin B is cleaved to 
give procathespin B in the endoplasmic reticulum. The 
protein is glycolated in the Golgi complex and, in 
nontransformed cells, the majority is transported to 
lysosomes through the mannose-6-phosphate signal pathway 
(Gal et al., 1985). A defect in this pathway in I-cell 
disease results in the release of lysosomal enzymes and the 
association of some lysosomal enzymes with small vesicles 
near the plasma membrane (van Dongen et al., 1985). A 
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similar process may occur in some transformed cells (Archkar 
et al., 1989). Within the lysosomal acid compartment, 
procathepsin B is processed to the single-chain mature form 
of cathepsin B (Steiner et al., 1984). 
Using a human cDNA to the cathepsin B as a 
hybridization probe, 2.2 and 4.1 kb mRNA species were 
detected in Northern blots of normal murine lines and murine 
melanomas (Fong et al., 1986). However, Qian reported that 
B16 melanoma variants contain 2.2, 4.0 and 5.0 kb mRNA 
transcripts for cathepsin B, but normal tissues only contain 
the 2.2 kb transcript (Qian et al., 1989; 1991a; 1991b) and 
Chambers et al., (1992) have observed a 4.0 kb cathepsin B 
mRNA in metastatic ras-transf ormed NIH 3T3 cell but not in 
non-metastatic variants. The larger transcripts are thought 
to be due to alternative polyadenylation site selection 
during the processing of the 3'-end of the cathepsin B mRNA 
(Qian et al., 1991a; 1991b). Variant messengers for 
Cathepsin B are also found in normal human tissue and 
tumors, and these arise as a result of alternative splicing 
of the 5 1 and 3 1 levels of the cathepsin B mRNAs (Gong and 
Frankfater, personal communication). 
Enzymology of cathepsin B 
The pH profile for cathepsin B activity is substrate-
dependent. The optimum pH is about 6.0 for synthetic 
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substrates such as carbobenzyloxy-L-arginine-L-arginine-2-
naphthylamide (Z-Arg-Arg-NHMec) (Barret and Kirschke, 1981). 
At pH 7.4 significant activity can be observed for times up 
to 12 hours if the assay is performed against large protein 
substrates that presumably stabilize the enzyme, provide 
resistance to inactivation by cysteine proteinase inhibitors 
(CPI) and physiological pH (Rozhin et al., 1987; 1990; Lah 
et al., 1989). Natural physiological substrates for 
cathepsin B are still a matter of speculation. Laminin, 
fibrinogen (Lah et al., 1989), fibronectin (Recklies et al., 
1982), trypsinogen (Figarella et al., 1988) are all degraded 
by tumor and liver cathepsin B at both acid and neutral pH 
in vitro (Lah et al., 1990; Sloane et al., 1990). Cathepsin 
B has been shown to be able to degrade proteins of the 
extracellular matrix including the non-helical regions of 
basement membrane type IV collagen, in vitro (Morrison et 
al., 1973; Burleigh et al., 1974; reviewed in Sloane and 
Honn, 1984). 
cathepsin B and Tumor Malignancy 
There is an extensive literature on the elevation of 
release of cathepsin B from both human and animal tumor 
cells in vitro (Sloane and Honn, 1984; Recklies, 1987). It 
is reported that a rise of cathepsin B activity was observed 
in human malignant breast tumors (Recklies et al., 1980), in 
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rat metastatic pancreatic cancer (Koppel et al., 1986), in 
murine B16 melanoma (Sloane et al., 1982), in Lewis lung 
carcinoma (Sloane et al., 1984), and in a rat sarcoma LW13K2 
(Krepela et al., 1989). 
Cathepsin B is released into extracellular fluid by 
breast tumor cells in organ culture in two major forms, a 
latent and an active form, with Mr precursor of 40 kD for 
both forms (Mort et al., 1980). The latent form can be 
activated with pepsin, resulting in the formation of a 33 kD 
active form of cathepsin B. A high Mr (40 kD) active form of 
cathepsin B was also reported in culture media of 
spontaneous mammary glands (Racklies et al., 1982) and 
lactating mammary glands (Recklies and Mort, 1985). The 
levels of a latent cathepsin B-like activities secreted by 
B16 melanoma variants parallels the metastatic capabilities 
of the variants (Qian et al., 1989). In addition, cathepsin 
B activity has been associated with the plasma membrane 
fractions of various tumor cell lines (Sloane et al., 1987; 
Sloane et al., 1986; Rozhin et al., 1990). An 
immunof luorescence study showed that the distribution of 
cathepsin B in cultured human colon carcinoma cells appears 
to be at the cell surface (Maciewixz et al., 1989). 
How cathepsin B is released by tumors or how it is 
associated with the plasma membrane-enriched fractions is 
not clear. It is suggested that either oversaturation of 
mannose-6-pathway and/or defects in the mannose-6-pathway 
could be involved in these non-lysosomal localization 
(Goldberg et al., 1983; Mainferme et al., 1985; Achkar et 
al., 1990; Pracht and Frankfater, unpublished data). 
structure of cathepsin L 
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Cathepsin L, another cysteine protease, is one of 
several acid protease-like cathepsins to be involved in the 
degradation of polypeptides within the lysosomes (Gottesman, 
1978). Full length cDNA clones encoding the entire cathepsin 
L precursor molecule have been isolated from both mouse 
(Troen et al., 1987; Portnoy et al., 1986; Joseph et al., 
1988) and human cells (Joseph et al., 1988; Gals. and 
Gottesman M. M., 1988). 
The exact cleavage sites involved in processed forms 
of lysosomal cathepsin L have been determined by comparing 
actual amino acid sequences of the mature protein and 
sequences deduced from the cDNA clones. 
Cathepsin L is synthesized as a prepropeptide 
containing a hydrophobic signal sequence of 17 amino acids 
which is cleaved to give procathepsin L. This protein is 
glycosylated in the Golgi complex and, in nontransformed 
cells, the majority is transported to the lysosomes through 
the mannose-6-phosphate pathway (Sahagian and Gottesman, 
1982). Within the acidic compartment, procathepsin Lis 
processed to the single-chain mature form via cleavage 
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between Lys 113 and Ile 114 (amino acid numbering starts 
with Met-1 of the signal sequence). This form can be further 
processed to the two chain species by cleavage between Ser-
290 and Asn-291. The large and small chains produced by this 
final cleavage remain associated by disulfide linkage(s) in 
the enzymatically active mature protein (Smith and Gottesman 
1989; Ritonja et al., 1988). 
Mature cathepsin L has been purified from a number of 
eukaryotic origins, including human kidney (Ritonja et al., 
1988), rat (Towatari and Katunuma, 1988), rabbit (Mason and 
Taylor, 1984), sheep (Mason, 1986), chicken (Dufour et al., 
1987) and human liver (Mason et al., 1985). In addition, the 
precursor form of the enzyme has been isolated from the 
cultured supernatant of transformed NIH/3T3 cells, which may 
secret abundant amounts of the protein (Gottesman et al., 
1978) . 
Enzymology of Cathepsin L 
Mature cathepsin L isolated from the lysosomes 
exhibits activity over a broad pH range, with maximal 
activity between pH 4.5-5.5. The mature enzyme retains 
activity, but is extremely unstable at neutral pH (Mason et 
al., 1985; Kirschke 1982). In contrast, procathepsin L, the 
secreted form of the protein, is very stable at neutral pH, 
but has little or no protease activity in that range 
(neutral pH), which suggests that propeptide might be 
involved in protein stabilization at neutral pH. 
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Mature cathepsin L is the most active lysosomal 
protease in vitro against a variety of neutral substrates, 
including aozcasein (Treen et al., 1987), elastin (Mason et 
al., 1986) and collagen (Kirschke et al., 1982). No absolute 
bond specificity of cathepsin L action has been determined, 
though it may show a preference for peptide bonds near 
hydrophobic amino acids (Mason et al., 1985). 
Cathepsin L can be distinguished from other 
cathepsins by its very limited activity in hydrolyzing some 
synthetic substrates. Z-Phe-Arg-NMe has turned out to be the 
most useful synthetic substrate for assaying cathepsin L 
activity (Kirschke et al., 1982). It is extremely 
susceptible to cathepsin L hydrolysis, but much less 
sensitive to proteolysis by cathepsin B, with Km values 
differing by as much as 20- to 50-fold for the two enzymes 
(Mason et al., 1985; Mason et al., 1987; Kirschke et al., 
1982) . 
Requlation of Expression of cathepsin L 
There are several reports on the regulation of 
cathepsin L synthesis by growth factors such as PDGF and EGF 
(Scher et al.; 1983, Nielsen-Hamilton et al., 1982), tumor 
promoters such as phorbol-myristate-acetate (PMA or TPA), 
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protein kinase A - cAMP (Kane and Gotterman, 1990), and ras 
oncogene transformation (Gottesman, 1979) which have been 
shown to increase cathepsin L synthesis in mouse fibroblast 
cells (Gottesman and Sobel, 1980). Increases of cathepsin L 
have also been reported to be associated with activation of 
macrophage (Portnoy et al., 1986), and on treatment of 
bovine endothelial cells with heparin (Cochran et al., 
1988) . 
cathepsin L and Tumor Malignancy 
A cathepsin L-like protein was first reported as a 
major excreted protein (MEP) whose extracellular and 
intracellular abundance was augmented when mouse fibroblasts 
were transformed by tumor viruses or methylcholanthrene 
(Gottesman, 1978). In subsequent work the protein was 
purified and shown to possess the lysosomal marker mannose-
6-phosphate (Sahagian and Gottesman, 1982). The sequence of 
MEP cDNA was determined and its deduced amino acid sequence 
was found to be identical to a partial protein sequence of 
cathepsin L (Troen et al., 1987). MEP was found to be the 
precursor to the lysosomal form of cathepsin L, i.e. 
procathespin L. Malignant transformation by several 
different oncogenes increases the rate of synthesis and 
secretion of procathepsin L (Gottesman 1979). A set of 
lOTl/2 cell lines that had been transfected by the T24-H-ras 
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oncogene revealed a positive correlation between metastatic 
potentials and MEP (Denhardt et al., 1987). 
Cysteine Proteinase Inhibitors (CPI) 
The cystatin superf amily of cysteine proteinase 
inhibitors (CPI) consists of three families: (1) the 
stefins, (2) the cystatins and (3) the kininogenes. In terms 
of inhibition of cathepsin B, the stefins and cystatins 
appears to be more physiologically important as their Kis 
for inhibition of cathepsin B are much lower than the 
kininogenes (Barret, 1987). 
The stef in family of CPis have been purified from 
human liver (Lah et al., 1989) and a human sarcoma (Sloane 
et al., 1989). They consist of proteins of about 11 kD that 
have no disulfide bonds or carbohydrate and exist primarily 
intracellularly. Two type of stefins have been identified: 
stef ins A with acidic isoelectric points and stef ins B with 
neutral isoelectric points. 
The cystatin superf amily is another class of natural 
proteins known to interact strongly with cysteine proteases 
in vivo (Barrett, 1987). These are reversible, competitive 
inhibitors. The cystatins may localize to the cell 
cytoplasm, resulting in inactivating lysosomal proteases 
that escape out of the lysosomes into other parts of the 
cell. Many of the cystatins can also be secreted into the 
extracellular environment and are found circulating in 
plasma. These inhibitors may serve as a further safeguard 
against cysteine proteases which have leaked out of cells, 
or they might be part of an intricate regulatory mechanism 
of extracellular protease activity (Kruithof, 1983). 
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Down-regulation of the synthesis of stef in A occurs 
during the progression of murine epidermal carcinomas from a 
pre-malignant to a malignant state {Hawley-Nelson et al., 
1988). A reduced amount was found in skin tumors (Jarvinen 
et al., 1987), and B16a tumors were found to have less 
stefin A than normal liver cells {Sloane, 1990). 
Analyzing the subcellular distribution of cathepsin 
L suggests that CPI might be involved in regulating of 
cathepsin L activity in murine B16 amelanotic melanoma cells 
(Rozhin et al., 1989). The plasma membrane fractions from 
B16 melanoma subpopulations of "low" and "high" metastatic 
potential were assayed for activity of cathepsin L and for 
heat stable endogenous cathepsin L inhibitors. The relative 
specific activity of cathepsin L was 7-fold greater in the 
subpopulation of "high" metastatic potentials, whereas 
cysteine proteinase inhibitory activity was 5-fold less. 
Tissue Inhibitor of Metalloproteinases (TIMP) 
The TIMPs are stoichiometric inhibitors of many 
mammalian metalloproteinases including collagenases that 
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degrade interstitial collagens (type I-III) as well as type 
IV and V collagens (Liotta et al., 1982; Goldfarb and 
Liotta, 1986; Torgeirsson et al., 1982). The TIMP family 
consists of at least two members. TIMP-1, first isolated 
from rabbit bone, is a glycoprotein with a core polypeptide 
of Mr 21,000 produced by many mesodermal tissues and is 
found in a wide variety of human body fluids and cells in 
culture (Welgus and Stricklin, 1983; Welgus et al., 1985). 
Determination of the molecular weight of the secreted, 
glycosylated protein ranged from 25,000 to 36,000 (Cawston, 
1986; Drouin et al., 1988). The human TIMP-1 has been 
isolated (Welgus et al., 1983), cloned and sequenced by 
several groups (Carmichael et al., 1986; Docherty et al., 
1985; Gasson et al., 1985). Mouse cDNA (Edwards et al., 
1986), and rabbit (Horowitz et al., 1989). cDNA clones have 
also been isolated. The encoded proteins of the murine and 
human TIMPs are 76% identical at the nucleotide level and 
73% identical at the amino acid level. Murine TIMP-1 has 
been mapped to the X-chromosome (Jackson et al., 1987). 
Human TIMP-1 is identical in amino acid sequence to a human 
collagenase inhibitor isolated from human fibroblasts 
(Carmichael et al., 1986) and also inhibits other neutral 
metalloproteinases with gelatinase, proteoglycanase, and 
stromelase activities (Heath et al., 1982; Sellers et al., 
1979) . 
The expression of TIMP-1 mRNA in murine fibroblasts 
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is induced by serum, platelet-derived growth factor, 
epidermal growth factor, and PMA (Edwards et al., 1986; 
Gewert et al., 1987; Denhart et al., 1986). A coordinated 
temporal regulation of metalloproteinases and TIMP have been 
observed in human fibroblasts which are induced to produce 
TIMP, and to suppress collagenase and stromelysin, under 
stimulation of transforming growth factor beta-1 (Machida et 
al., 1988; Overall et al., 1989). 
Natural TIMP-1 has been shown to inhibit tumor cell 
invasion of the human amnion, which models invasion of tumor 
cells across the basement membrane and stroma in vitro 
(Torgeirsson et al., 1982; Mignatti et al., 1986). The most 
direct evidence of metalloproteinase involvement in cancer 
metastasis has came from this laboratory which showed that 
human recombinant TIMP acts as an inhibitor of tumor cell 
invasion in the in vitro amnion membrane invasion assay and 
in an in vivo lung colonization assay with B16 FlO melanoma 
cells in C57BL/6 mice (Schultz et al., 1988). 
TIMP-2 is nonglycosylated and has recently been 
isolated from media conditioned with human melanoma cells 
(Stetler-Stevenson et al., 1989) or bovine endothelial cells 
(De Clerck et al., 1989). TIMP-2 shares a 43% amino acid 
sequence homology with the TIMP-1 and is found as a complex 
with the 72-kD type IV procollagenase, an enzyme closely 
linked to the invasive phenotype of both human melanoma and 
endothelial cells (Goldberg et al., 1989). 
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structure of Mammalian Ras 
All the properties of both normal and malignant cells 
are determined by the subset of those genes expressed in 
their genome. A number of these genes have been shown to 
have a role in the process of malignant transformation and 
have been termed oncogenes. Oncogenes are derived from 
normal genes (proto-oncogenes or cellular oncogenes) that 
are highly conserved in evolution and that code for proteins 
that have important roles in normal cellular processes such 
as the regulation of gene expression or the transduction of 
growth signals. Of the 50 to 60 oncogenes so far identified 
as capable of transforming cells, the ras family of 
oncogenes are among the most frequently activated in human 
cancer (reviewed by Bos, 1989). 
The ras genes include (at least) three well-
characterized genes that have been associated with human 
cancers: Harvey-ras (H-ras), Kirsten-ras (K-ras), and N-ras 
(Barbacid, 1987; Bos, 1989). All of the three ras genes code 
for closely related 21-kD proteins that can bind GDP and 
GTP, and also have intrinsic GTPase activity which functions 
to convert Ras-GTP to Ras-GDP. Rates of GTP hydrolysis by 
wild-type Ras protein, but not oncogenic protein, are vastly 
elevated in vivo (Trahey and MoCormick, 1987). The 
discrepancies led to the discovery of GAP, a GTPase-
activating protein found ubiquitously in cell. The carboxy-
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terminal 40K acts catalytically upon wild-type Ras proteins 
to stimulate their hydrolysis of bound GTP, but fails to 
stimulate GTP hydrolysis by mutant oncogenic Ras (Marshall 
et al., 1989). The ras proteins share structural homology 
with G proteins and play a role in the transduction of 
growth signals. The transforming potential of ras proteins 
(p21) is usually associated with a point mutation in the 
codons encoding amino acids 12, 13, or 61 (Sistonen and 
Alitalo, 1986). These critical amino acid substitutions all 
occur in or near the GTP binding domain of the protein, and 
the transforming potential of altered p21 is associated with 
the loss of GTPAse activity. This view has been recently 
confirmed by crystallographic studies of the protein (Tong 
et al., 1989) 
Ras proteins are in the cytosol and become associated 
with the inner side of the plasma membrane for functional 
activity. Mutations at the cysteine of the COCH-terminal 
Cys-a-a-X box (where a is an aliphatic amino acid and X any 
of the common amino acids) generate an inactive cytoplasmic 
protein by blocking a complex series of post-translational 
modifications that includes removal of the three terminal 
amino acids and polyisoprenylation of the new COCH-terminal 
cysteine (Hancock et al., 1989). The Cys-a-a-X box is a 
general signal for addition of the 15-carbon farnesyl lipid 
moiety which increases the hydrophobicity of the protein, 
but a further signal is required for targeting to specific 
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membranes (Holtz et al., 1989). Localization of N-ras and H-
ras to the plasma membrane requires addition of palmitic 
~
acid at another cysteine residue (181 or 184). In cellular 
Ki-ras, which does not contain an upstream cysteine and is 
not palmitoylated, a region rich in basic amino acids 
(residue 175-182) seems to provide this additional signal 
(Holtz et al., 1989). 
Functions of Mammalian Ras 
Genetic analysis of mammalian Ras is not yet possible 
and biochemical approaches have been used to analyze its 
function. Although the ~ genes cannot be deleted, the 
proteins can be neutralized by microinjecting antibodies to 
Ras into cells treated with growth factor (Mulcahy, 1985). 
The result shows that the ras product is essential during 
the first 8 hours of the G1 phase of the cell cycle. After 
this time cells are committed to complete G1 , enter the s 
phase, and complete a cycle. 
Although mutationally activated ras genes suffice to 
transform NIH 3T3 mouse fibroblasts in vitro, a single 
genetic event is probably not sufficient to cause human 
cancers. In fact, it is believed that as many as five or six 
steps are required for human malignancies (Weinberg, 1989). 
The cooperation of ras genes with other oncogenes has been 
elegantly shown in the now classic experiments of Land and 
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coworkers (Land et al., 1983). Rat embryo fibroblasts (REF 
cells) could be transformed only when at least two different 
oncogenes were introduced: a myc-like and a ras-like gene. 
so far, little progress in identifying the Ras 
signaling pathway has been made from analyzing changes in 
second messengers. It is not known whether Ras controls the 
classical growth factor responses such as phospholipid 
turnover and protein kinase activation or whether it 
generates a novel signal. 
structure and Function of Ras in yeast §. cerevisiae. 
Saccharomyces cerevisiae contains two genes, RASl and 
RAS2, which produce ras-like gene products. The RASl and 
RAS2 proteins contain 309 and 322 amino acids, respectively, 
compared to the mammalian p21 of Ha-ras protein with 189 
amino acids. Alignment of the sequence of the mammalian p21 
with RASl and RAS2 proteins show the yeast Ras contains 
seven additional amino acids on the NH2-terminal end and the 
rest of the additional amino acids (except for one) are 
added to the COCH-terminal end of the p21-ras sequence. The 
first 80 amino acids of mammalian Ha-ras show a greater than 
90% identity to the near NH2-terminal sequences in the yeast 
RAS proteins (residues 8 to 88), and the next 80 amino acids 
show nearly 50% identity (Powers, et al., 1984). 
Based on their extensive sequence and structural 
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homology, yeast and mammalian Ras proteins show an apparent 
functional homology. Mammalian ras can substitute for yeast 
RAS genes in~ cervisiae (Kataoka, et al., 1985). In turn, 
mutated RASl can transform mammalian cells (Bradley, et al., 
1986) . 
Genetic analysis has provided important insights into 
the function of the ras proteins in this organism. Deletion 
of both RASl and RAS2 genes, for example, is lethal, but 
cells can be rescued by the gene (BCYl) encoding the 
regulatory subunit of the cAMP-dependent protein kinase 
(Toda et al., 1985). This RAS-deficient strain can be 
stimulated in vitro by addition of recombinant Ras protein 
of yeast or mammalian source (Broek et al., 1985). There is 
no doubt that in S. cerevisiae Ras proteins regulate 
adenylate cyclase activity and cAMP concentrations (Broek et 
al., 1989). There is still some doubt, for example, whether 
Ras activates adenylate cyclase directly or through an 
intermediary cyclase-associated protein (CAP), and there is 
strong genetic indication that Ras controls another 
additional signaling pathway distinct from adenylate cyclase 
but essential for cell viability (Field et al., 1990). The 
proteins encoded by IRAl and IRA2 genes both have homology 
to mammalian GTPase activating protein (GAP). Strains 
deleted in IRAl can be rescued by introducing the mammalian 
GAP gene (Tanaka et al., 1990). These finding suggest that 
IRAl and IRA2 encode GAPs involved in the down-regulation of 
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Ras. 
Tumor Promoting Phorbol Esters 
Tumor promoting phorbol esters were isolated from the 
oil of the Euphorbiacea Croton tiglium L and structurally 
identified to be a diacylgly~erol analog (Hecker 1968; van 
ouuren et al., 1965). The most potent phorbol ester is 
phorbol-12-myristate-13-acetate (abbreviated as PMA or TPA). 
one of the best known effects of PMA is to enhance 
transformation of cells to tumor cells (Blumberg et al., 
1988). PMA can induce normal cells into the tumor initiation 
stage of carcinogenesis (Slaga, 1984). 
In addition to its tumor promoter property, PMA has 
been found to have a pleiotropic action on cells causing 
alterations in the state of differentiation, proliferation, 
metastatic potentials and the expression of specific genes 
(O'Brian and Ward, 1989; Weinstein, 1988; Blumberg, 1988). 
PMA binds to and directly activates the phospholipid-
dependent protein kinase C -(PKC), a major protein in the 
inositol phosphate signal transduction pathway (Nishizuka, 
1988; Person et al., 1988). The activation of PKC by PMA 
mimics the action of the inositol phosphate generated 
diacylglycerol on PKC (Castagna et al., 1982; Ashendel, 
1985). Activated PKC binds to the plasma membrane and 
through its catalytic phosphorylations on substrate 
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effectors, which have not yet been identified, induces the 
described pleiotropic changes (Kiss, 1990). A part of its 
action is to increase the expression of the early response 
oncogenes, c-fos, c-myc and c-jun (Abate and Curren, 1990). 
The c-Fos protein and c-Jun protein form the AP-1 complex 
which binds to the PMA or TPA response elements (TREs) 
present in the phorbol ester responsive genes (Abate and 
Curran, 1990; Chiu et al., 1988; Sassone-Corsi et al., 1988; 
Lamph et al., 1988). 
The mechanism of activation of PKC by phorbol ester 
is still a open question. The protein kinase C (PKC) family 
of phospholipid-dependent protein kinases play a key role in 
signal transduction. The PKC isoenzymes are normally 
activated by diacylglycerol (DAG), one of the products of 
the receptor-mediated hydrolysis of inositol phospholipid, 
and also by certain drugs, including the phorbol ester tumor 
promoters. PKC isoenzymes consist of a catalytic (carboxyl-
terminal half) and a regulatory domain (amino-terminal half) 
(Nishizuka,1988). The catalytic domain contains sequences, 
including an ATP-binding site, that resemble other protein 
kinases. All PKC isoenzymes contain a so-called 
pseudosubstrate motif and a tandem repeat of cysteine-rich 
sequence in their regulatory domain (Nishizuka, 1988). The 
central motif of the pseudosubstrate region (RKGALR) is 
identical in sequence and position in PKC isoforms a, b and 
rPKC (House and Kemp, 1987). It has been suggested that 
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cysteine-rich regions in PKC are essential for phorbol-ester 
binding (Ono et al., 1989). It is possible that the phorbol 
ester as well as DAG are hydrogen-bonded to the sulfhydryl 
groups in these cysteine-rich regions (Gechwendt, 1991). 
PMA is known to induce the expression of genes coding 
for collagenase (Whitham et al., 1986), stromelysin 
(Matrisian et al., 1985), urokinase (Degen et al., 1985; 
collart et al., 1986; Bell et al., 1990), cathepsin L 
(Gottesman and Sobel, 1980) and metallothionein (Imbral and 
Karin, 1987; Angel et al., 1987). These proteins may play a 
role in invasion and metastasis (Mignatti et al., 1986). 
Some products of proto-oncogenes, such as the products of 
sis (Colamonici et al., 1986), myc (Greenber and Ziff, 1984; 
Kelly et al., 1983), pro-1 (Lerman and Colburn, 1987), fos 
(Kruijer et al., 1984), and c-Ha-~ (Balmain et al., 1984; 
Weinstein, 1987) are potential targets for PKC. The most 
direct evidence for PKC involvement in tumor metastasis is 
from an experiment that pre-treats B16 melanoma cell 
sublines with PMA and shows promotion of the metastatic 
potential of these treated cells in a lung colonization 
assay (Gopalakrishna and Barsky, 1988). 
Materials 
CHAPTER III 
MATERIALS AND METHODS 
Zeta-probe filters were from Bio-Rad (Richmond, 
CA.), a-32P-dCTP and a-32P-UTP (specific activity 3,000 
ci/mmol) were from ICN Biomedicals, Inc., (Irvine, CA). NACS 
PREPAC CARTRIDGE and the Nick Translation System were 
purchased from BRL Life Technologies, Inc., Geithersburg, 
MD. Kodak X-OMAT AR Diagnostic Film was from Eastman Kodak 
Co. (Rochester, NY). Intensifying screen (Dupont Cronex 
Lighting Plus GJ 220004) was purchased from Dupont Co. 
(Wilmington, DE). Polyclonal antibodies against human PAI-2 
and goat anti-mouse antibody were purchased from American 
Diagnostica Inc., (New York, NY). The BCA protein assay kit 
was from Pierce Chemical Company, Rockford, Ill. 
The cell culture supplies were purchased from either 
Flow Laboratories (McLean, VA) or Gibco Laboratories (Grand 
Island, NY). 
The substrate for uPA enzymatic activity analysis, s-
2251 (H-D-Val-Leu-Lys-p-nitroanilide) was purchased from 
KabiVitrum, Stockholm, Sweden. The substrate for cathepsin L 
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enzymatic activity analysis, N-carbobenzoxy-L-Phe-L-Arg-7-
aminomethylcoumarin (Z-Phe-Arg-AMC), was from BACHEM 
Bioscience Inc. (Philadelphia, PA). 
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The mouse uPA cDNA plasmid was a gift of D. Belin 
(University of Geneva), the mouse CL cDNA was a gift of L. 
Joseph and V. P. Sukhatme (University of Chicago), the mouse 
CB cDNA was a gift of s. J. Chan (University of Chicago), 
human uPA cDNA was from W. E. Holmes, (Katholieke 
Universitert Leuven, Belgium), human TIMP cDNA was a gift of 
D. F. Carmicheal (Synergen Company, Colorado), human PAI-1 
cDNA was from D. J. Loskutoff (Scrips Institute, La Jolla, 
CA), and human PAI-2 cDNA was a gift from J. E. Sadler 
(Washington University, st. Louis, MO.). Drosophila actin 
was from Dr. Mark Kelly (Loyola University of Chicago), and 
human glycerol aldehyde phosphate dehydrogenase cDNA 
containing plasmid was obtained from American Tissue Culture 
Collection. 
Mouse cathepsin B (1,130 base pairs (bp) (Chan, 
1986), mouse uPA (1,000 bp) (Belin, 1985), mouse cathepsin L 
(1,100 bp) (Joseph et al., 1988), human uPA {880 bp) {Holmes 
et al., 1985), human TIMP {800 bp) {Carmicheal et al., 
1988), PAI-1 {3,000 kb) {Loskutoff, 1985), human PAI-2 
{l,800 bp) {Sadler, 1987) cDNA fragments were prepared in 
this laboratories. Enzymes and chemicals were purchased from 
Bethesda Research Laboratories {BRL, Geithersburg, MD) and 
Boehringer Mannheim Biochemicals {Indianapolis, IN). All of 
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these fragments were obtained by digesting the plasmids with 
the endonuclease suggested by the providers, and the 
resulting digested patterns are consistent with the 
published literatures. The endonucleases utilized to 
digested these plasmids to obtain the fragments for Northern 
hybridization are discussed below, under Electrophoresis and 
Northern Blot Analysis. 
cell Lines 
Non-transformed NIH 3T3 and NIH 3T3 murine 
fibroblasts transfected with 4 different ras oncogene 
constructs were obtained from M. o. Bradley (Merck Research 
Institute, West Point, PA), and have been characterized with 
respect to their metastatic potential in nude mice (Bradley, 
et al., 1986). Their characteristics are shown on Table 1. 
The PC3-P and PC3-M cell lines, which are human 
prostate carcinoma cell lines, were obtained from Dr. James 
Kozlowski (Northwestern University, Chicago, Ill.). The PC3-
M cells are highly metastatic in the nude mice, while the 
PC3-P (parental) cells have a significantly lower metastatic 
potential (Kozlowski, et al., 1984). 
A375-P & A375-M cells lines, derived from a human 
melanoma, were kindly provided by Dr. I.J. Fidler 
(University of Texas, M. D. Anderson Medical Center, 
Houston, TX). A375-P cells show a low metastatic potential 
in nude mice and A375-M is a high metastatic derivative 
(Kozlowski et al., 1984). A summary of major properties of 
above two cell lines are in Table 2. 
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The PC3-P and M cells were grown in Eagle's minimal 
RPIM 1640 supplemented with 10% heat-inactivated fetal 
bovine serum (HI-FBS) (Flow Laboratory, McLean, VA) and 100 
units/ml of penicillin and 100 ug/ml of streptomycin sulfate 
(Gibco Laboratories) • 
The A375-P and SM cells were grown in Eagle minimal 
essential medium (MEM) supplemented with 10% heat-
inactivated fetal bovine serum (HI-FBS) (Flow Laboratory, 
McLean, VA), 1% MEM nonessential amino acids (Gibco 
Laboratories, Grand Island, NY), 1 mM sodium pyruvate, 1 mM 
MEM vitamin solution, 100 units/ml of penicillin and 100 
ug/ml of streptomycin sulfate (Gibco Laboratories). 
For the subculture of these human cells, the cells 
were detached from the cell culture flask by using 1 mM of 
ethylenediamine tetracetic acid (EDTA) in phosphate buffer 
saline (EDTA-PBS), pH 7.4, and were split 1:5. 
All cell lines discussed above were incubated at 37°C 
in 5% C02 saturated with water vapor and maintained by 
changing the medium every 2-3 days. The total number of 
passages was less than 3 to keep the genetic drift of the 
cells to minimal levels. 
Medium and supplements used in these cell cultures 
are summarized in Table 3. 
CELL LINE 
NIH/3T3 
EJ-ras 
EJ/vHA-ras 
HYB CLeu 
Table 1 Characteristics of ras Oncogenes Transf ected 
NIH 3T3 Fibroblasts 
(Data from Bradley et al., 1986) 
ONCOGENE CONSTRUCT 
Ras Proto-oncogene 
Human Bladder Carci-
noma T-24 
Chimeric Human 
and Viral-oncogene 
Chimeric Yeast 
and Viral-oncogene 
Recombinant Yeast 
Oncogene 
Ras MUTATION8 
Gly12 , Ala59 , Gln61 , 
Val12 , Ala59 , Gln61 , 
Val 12 , Thr59 , Gln61 , 
19 66 68 Gly , Ala , Leu , 
19 66 68 Gly , Ala , Leu , 
Average No. of 
tumor per lung 
0 
9 
72 
>280° 
S.D. 
0 
14 
32 
40 
29 
8underlined amino acid represents a mutation from normal amino acid of cellular Ras protein 
at designated position 12, 59 or 61. In yeast sequence position 19, 66 and 68 are equivalent 
to 12, 59, 61 of mammalian Ras. 
bNumber of injected cells was 2.9 x 105 per mice. 
0 Number of injected cells was 1.8 x 105 per mice. w O'I 
TABLE 2 Experimental Metastasis of Human Tumor Cells 
in Nude Mouse 
(Data from Kozlowski et al., 1984} 
Cell Line origin 
A375-P Human Melenoma 
A375-M Human Melenoma 
PC3-P Human Prostate 
Carcinoma 
PC3-M Human Prostate 
Carcinoma 
median no. of 
apparent lNng tumor 
nodules 
0 {0-5}c 
69 (0-250) 
0 
38 (0-250) 
no. of animals with 
microsco~c metastases 
in lung 
2/5 
5/5 
1/15 
13/15 
aNumberof grossly apparent tumor foci on lung surface were determined with the aid of a 
dissecting microscope. 
bstepwise sections from lungs of each animal were examined for present of microscopic 
parenchymal metastases. 
cNumber in parentheses, range. 
w 
-....] 
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TABLE 3 Culture Medium of Cell Lines 
Name Species Medium supplement Detachment media 
------------------------------------------------------------
NIH/3T3 mouse 
EJ-ras mouse 
EJ/vHa-ras mouse 
HYB C mouse 
mouse 
PC3-P human 
PC3-M human 
A375-P human 
A375-SM human 
DMEM 
DMEM 
DMEM 
DMEM 
DMEM 
10% HI-FBS8 
gentomycin 
10% HI-FBS 
gentomycin 
10% HI-FBS 
gentomycin 
10% HI-FBS 
gentomycin 
10% HI-FBS 
gentomycin 
RMPI 1640 10% HI-FBS 
b S. P. 
RMPI 1640 10% HI-FBS 
s. p. 
MEM 
MEM 
10% HI-FBS 
S. P. 
10%-HI-FBS 
S. P. 
0.1% trysin & 
1 mM EDTA 
0.1% trysin in 
1 mM EDTA 
0.1% trysin & 
1 mM EDTA 
0.1% trysin & 
1 mM EDTA 
0.1% trysin & 
1 mM EDTA 
1 mM EDTA 
1 mM EDTA 
1 mM EDTA 
1 mM EDTA 
8 HI-FBS: heat-inactivated fetal bovine serum. 
bS.P.: streptomycin 100 ug/ml and pencillin 100 units/ml. 
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Preparation of mRNA 
Northern blots were used to study the correlation 
between steady-state mRNA levels of the genes and metastatic 
potentials. The procedure for preparation of glasswares and 
the solutions were ones described by Maniatis (1984). The 
cultured cells were washed with cold phosphate-buffer saline 
(PBS), removed from the flasks with 1 mM EDTA-PBS and 
pelleted by centrifugation. The pellet was resuspended with 
1 ml of 10 mM Tris (pH 7.9), 1.5 mM MgC12 , and 0.15 M NaCl. 
The suspension was mixed with 200 ul of detergent solution 
containing 10 mM Tris, 1.5 mM MgC12 , 1.5 mM MgC12 , 0.15 M 
NaCl and 13% NP-40, and kept in ice for 10 min. The nuclei 
were pelleted at 10,000 rpm, the supernatant was poured into 
a 30 ml Corex tube with 1 ml of buffer (10 mM Tris, 0.35 M 
NaCl, 5 mM EDTA, 1% sos and 7 M urea), 2 ml phenol and 6 ml 
chloroform. The pellet was saved at -70°C for later nuclear 
transcription assays. The initial supernatant was 
centrifuged again and the upper liquid portion was 
transferred to a clean tube. After the addition of 2.5 
volumes of cold ethanol, the tube kept at -20°c overnight. 
The RNA precipitate was obtained by centrifuging at 10,000 
rpm for 20 min. The concentration of RNA was determined with 
a UV spectrophotometer at 260 nm (Maniatis, 1982). 
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Electrophoresis and Northern Blot Analysis 
The poly(A) rich RNA was obtained using poly(dT) 
resin chromatography (BRL). The resulting RNAs were 
separated overnight by electrophoresis in 1% agarose, 0.02% 
formaldehyde gel in MOPS buffer (0.2 M MOPS, 0.05 M sodium 
acetate, 0.01 M EDTA) at 25 v. The RNAs were transferred to 
zeta-probe Membrane (Bio-Rad, CA) by the capillary transfer 
method in 20 x SSC (lx SSC = 0.15 M NaCl, 0.015 M sodium 
citrate, pH 7.0) overnight and immobilized by the UV 
crosslinking technique (UV Stratalinker 1800, stratagene, La 
Jolla, CA). For preparation of the respective cDNA probes, 
the mouse uPA cDNA containing plasmid was double digested 
with Hind III/EcoRl; the mouse cathepsin B plasmid was 
double digested with Hind III/EcoRl; the mouse cathepsin L 
plasmid with BamHl, the human TIMP plasmid with EcoRl; human 
PAI-1 plasmid with EcoRl; human PAI-2 plasmid with EcoRl. 
The DNA fragments were separated in 1% low-melting agarose 
(Sigma Chemicals Co.) by electrophoresis and the fragments 
of interest were identified by their expected molecular 
weight, and isolated from the gel by razor blade. 
The fragments were labeled with 32-P-dCTP by a random-
primer labeling kit (Boehringer Mannheim Biochemicals). 
Briefly, DNA fragments were first denatured by heating for 
10 min at 95°C and subsequently cooling on ice. The DNA 
hexanucleotide mixture, 2 U Klenow enzyme and 50 uci of 32-
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p-dCTP were mixed with a buffer solution containing 0.25 mM 
dATP, dGTP, dTTP, the reaction carried on in 37°C for 1 hr, 
and unincorporated 32-P-dCTP separated with a NACS Prepac 
cartridge (BRL) . 
Sometimes labeling was carried out by the nick 
translation procedure (Nick Translation System, BRL Life 
Technologies, Inc., Geithersburg, MD). The plasmid DNA was 
added to the reaction mixture containing dATP, dGTP, dTTP, 
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and -P-dCTP (ICN Biomedicals, Inc., Irvine, CA) and nick-
translated by incubation with 1 U of DNA polymerase I and 
100 pg of DNase I at 15°C for 60 min. 
The labeled DNA fragments were hybridized in to the 
filter bound in RNAs in a hybridization solution containing 
0.5 M NaH2P04 pH 7.2, 0.25 M EDTA and 1% bovine serum 
albumin at 65°C overnight. The filter was washed 2 times for 
30 min each with 10 mM EDTA, 40 mM NaH2P04 , 0.5% bovine 
serum albumin fragment V (Boehringer Mannheim Biochemicals) 
and 1% sos; and two times for 30 min each with 10 mM EDTA,40 
mM NaH2P04 , 1% SOS. The filter was exposed to X-ray film 
(Kodak X-OMAT AR Diagnostic Film, Eastman Kodak Co., 
Rochester, NY) at -70°C with an intensifying screen (Dupont 
Cronex Lighting Plus GJ 220004, Dupont co., Wilmington, DE). 
To estimate the relative amounts of hybridization, the 
autoradiograms were scanned with a Beckman Densitometry 
System or other similar densitometer. For rehybridization, 
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the attached probe was removed by washing the filter at 95°C 
2 times for 20 min each in 0.1 x SSC containing 0.5% sos. 
The filter was exposed to X-ray film to check the efficiency 
of the stripping. The stripped filter was then rehybridized 
as described above. 
For the internal standard control, the filter was 
similarly hybridized with either 32P-labeled plasmids 
containing the Drosophila actin cDNA (Fryberg et al., 1983) 
obtained from Dr. Mark Kelly (Loyola University Medical 
center) or a human glyceraldehyde-3-phosphate dehydrogenase 
(GAPD) (American Tissue Culture Collection), and the labeled 
filter exposed to X-ray film. 
Time Course of Stimulation of Protease and Anti-
Protease Genes by Phorbol Ester 
Phorbol ester stimulation of gene expressions of 
proteases and protease inhibitors were assayed by the slot 
and Northern blot techniques. In these procedures the cells 
were grown in T-75 culture flasks (GIBCO, Grand Island, NY) 
until subconfluent. The culture medium was then removed and 
10 ml fresh medium with 10% heat-inactivated fetal bovine 
serum (HI-FBS) and 20 nM phorbol-12-myristate-13-acetate 
(PMA, Sigma Chemical Co.) was added. After incubation with 
PMA for 2, 4, 8, 16, and 32 hr, the cells were harvested in 
phosphate buffer saline containing 1 mM EDTA (PBS-EDTA) and 
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centrifuged at 500 x g. The cells without PMA treatment, 
designated o hr, was used as the unstimulated control. The 
cytoplasmic RNA was extracted (see above). A Zeta-probe 
filter was soaked in deioned water for 30 min, and the 
filter was placed in a slot blot apparatus (Bio-Rad). RNAs 
were denatured by incubating in a solution containing 45% 
formamide, 0.01 M MOPS {Sigma Chemical Co.), 0.05 M sodium 
acetate, 10 mM EDTA, 20% formaldehyde, 7.5% glycerol at 95°C 
for 10 min. The filter was then rinsed in a solution 
containing 10 mM NaOH and 1 mM EDTA, and hybridized with 
32P-labeled probes by the procedure described previously. 
Northern blots were performed with RNA samples at a given 
time points to verify the observations based on slot blots. 
Run-on Assay for Transcription Rate 
Increases in mRNA steady-state concentration may be 
due to either an increased rate of synthesis or to a 
decreased rate of degradation. In order to determine the 
mechanism for the changes in mRNA levels observed in slot 
blot procedure, run-on assays were carried out. 
The procedure was as described by Nevins, 1987. 
Nuclei, prepared as previously described in the section on 
preparation of mRNA above, were washed in the reaction 
buffer {20 mM Tris, pH 7.9; 20% glycerol; 140 mM KCl; 10 mM 
MgC12 ; 1 mM dithiothreitol; 1 mM each ATP, CTP, GTP). The 
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nuclei were quickly frozen in liquid nitrogen and stored at 
-10°c in a freezer. 
Nuclei were resuspended in reaction buff er containing 
nucleotide triphosphates, alpha-32P-UTP {ICN Biomedicals, 
Inc., Irvine, CA) and creatine kinase (BRL, Geithersburg, 
MD). The nuclei were incubated at 37°C for 10 min. The 
reaction was stopped by the addition of a 1 ml solution 
containing 10 mM Tris {pH 7.4), 0.5 M NaC12 , 50 mM MgC12 and 
2 mM CaC12 to lyse the nuclei. The unincorporated label was 
removed by a 3 times repeated ethanol precipitation of the 
labeled product. Labeled RNA was dissolved in 200 ul of 0.02 
M Tris-HCl {pH 7.4), 1 mM MgC12 and incubated with 50 ug/ml 
DNase {Sigma Chemical Co.) at 37°C for 15 min. DNase was 
removed by extraction with phenol-chloroform. The RNA 
product was fragmented by incubating with 0.2 N NaOH on ice 
for 30 min, and an aliquot was removed for measuring 
incorporated radioactivities with a Beckman LS 7500 Liquid 
Scitilation System. 
The plasmids containing the cDNAS for the genes of 
interest were denatured by boiling the DNA in 0.1 N NaOH for 
10 min. A nitrocellulose filter (Bio-Rad) was washed with 6 
x SSC {l X SSC = 0.15 M sodium acetate, 0.15 M sodium 
chloride). The denatured cDNA-containing plasmids were 
slowly loaded onto the filter. The filter was washed with 6 
x SSC, dried, and baked in a vacuum oven at 80°C for 2 hr. 
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The dried filter was first incubated in 
prehybridization buffer containing 50 mM HEPES (pH 7.4), 0.3 
M NaCl, 10 mM EDTA, 0.2% SOS, 1 mg/ml yeast tRNA (Boehringer 
Mannheim Biochemicals, Indianapolis, IN), 0.5 mg/ml poly(A), 
1% sodium pyrophosphate, 5 x Denhards't solution ion (1 x 
oenharht 'solution equal 0.02 % polyvinylpyrilidone, 0.02% 
bovine serum albumin, 0.02% Ficoll 400 and 0.02% BSA) 
without albumin for 60 hr and replaced with hybridization 
buffer containing 50 mM HEPES (pH 7.4), 0.3 M NaCl, 10 mM 
EDTA, 0.2% sos, 100 ug/ml yeast tRNA, 100 ug/ml poly(A), 
o.1% sodium pyrophosphate, 1 x Denhardt's solution and equal 
counts of the labeled RNA. The filter was incubated at 65°C 
for 36-40 hr, washed 3 times with 2 x SSC at 65°C for 30 
min, and treated with a mixture of Tl RNase (5 U/ml, 
Borhringer Mannheim Biochemicals) and pancreatic RNase (2.5 
ug/ml, Sigma Chemical Co.) in 2 x SSC for 1 hr at 37°C. 
After digestion, the fluid was removed, and the filter was 
washed 2 times with 2 x SSC at room temperature for 30 min. 
The filter was then exposed to X-ray film (Kodak X-OMAT AR 
Diagnostica Film, Eastman Kodak Co., Rochester, NY) at -70°C 
with an intensifying screen (Dupont Cronex Light Plus GH 
220004, Dupont Co., Wilmington DE). 
Enzyme Assays for cathepsin L 
NIH/3T3 fibroblasts, EJ/vHa-ras and RAS11eudel-
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transformed NIH/3T3 fibroblasts were cultured 50,000 
cells/well in 24-well flasks (Flow Laboratories). The cells 
were grown in Dulbecco•s modified Eagle's minimal essential 
media (DMEM) with 10% heat-inactivated FBS and 50 ug/ml 
Gentamicin until subconfluent (80-90%), washed with PBS and 
incubated in serum-free media for 24 h, the media collected, 
and centrifuged at 10,000 rpm in Beckman Microfuge E. 
The cells remaining in the wells were lifted with 1 
mM EDTA in PBS and counted in a model ZBI Coulter counter, 
the cells lysed with 1% sos and 1 mM EDTA in PBS, and 
dialyzed against PBS for overnight in the cold room with 3 
times changes. The resulting preparation were saved in -20 
0c. The substrate N-carbobenzoxy-L-Phe-L-Arg-7-
aminomethylcoumarin (Z-Phe-Arg-AMC) (BACHEM Bioscience Inc. 
Philadelphia, PA) was used to assay for cathepsin L (Mason, 
1986; Baricos, et al., 1988). Both cathepsin Band L can 
catalyze the hydrolysis of this substrate. Based on the kcat 
and Km already reported for these substrates with the two 
enzymes from human and rat (Mason, 1986; Baricos, et al., 
1988) at the substrate concentration of 5 uM, the cathepsin 
L/cathepsin B activity ratio for Z-Phe-Arg-AMC was 
calculated to be 9 to 1. Procathepsin L in the cells was 
activated by pepsin (3900 units/mg protein, Sigma). The 
optimal concentration of pepsin for activation of 
procathepsin L was 1-2.5 mg/ml, which was determined 
experimentally by varying the pepsin concentration stock 
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solution (between O and 10 mg/ml in 0.2 M sodium acetate, pH 
4 .2) in activation buffer (30 mM dithiothreitol and 15 mM 
EDTA, pH 5.2) for 30 min at 37°C. The activity of the 
activated enzyme was measured by the addition of 0.8 ml of 
0.2 M Na citrate/Na phosphate at pH 6.2 containing Z-Phe-
Arg-AMC at final concentration of 5 uM .• The appearance of 
product 7-aminomethylcoumarin (AMC) was followed in a SLM-
Aminco SPF-500 c spectrof luorometer at room temperature at 
excitation and emission wavelengths of 370 and 450 nm, 
respectively. 
Enzyme Assay for uPA 
Urokinase plasminogen activator activity was measured 
spectroscopically using a chromogenic substrate for plasmin 
as previously described by Whur et al., 1980. The 
plasminogen was pre-treated with diisopropylf luorophosphate 
(DFP), to inhibit any active plasmin activity present. 
Specifically, plasminogen was incubated with 25 mM DFP in 50 
mM Tris buffer, pH 8.1, at 37°C for 1 hour, and then 
extensively dialyzing against the same buffer. Plasmin 
activity was measured in the DFP-treated plasminogen to 
ensure endogenous activity was undetected by the assay. 
Fifty ul of the medium was added to 100 ul of 100 mM 
Tris buffer, pH 8.1, containing 5 ug of DFP-treated 
plasminogen (Sigma Chemical Co.), 15 ug of S-2251 (H-D-Val-
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Leu-Lys-p-nitroanilide, KabiVitrum, Stockholm, Sweden), and 
o.1% Triton X-100. After incubating for 16 hr at 37°C, the 
concentration of p-nitroaniline, corresponding to substrate 
hydrolysis by plasmin, was read at 405 nm in a Perkin-Elmer 
320 spectrometer. 
The background activity was determined by 
substracting reaction buffer for conditioned medium, and 
each subtrasting the background from each reading. Each 
experiment was performed in three separate wells. 
Plasminogen activator activity was expressed in absorbance 
6 per 10 cells per hour. 
Antisense Oligodeoxynucleotides Transf ection 
The mouse urokinase gene (Degen et al., 1987) and the 
mouse cathepsin L cDNA (Troen et al., 1988) have been 
sequenced. The three 21-mer oligonucleotides sense-uPA (5'-
ATGAAAGTCTGGCTGGCGAGC-3 1), anti-uPA (5'-
GCTCGCCAGCCAGACTTTCAT-31), anti-CL (5 1-
CAAAAGGAGTAAAAGATTCAT-3 1) were made. The anti-uPA and anti-
CL sequences were in an antisense directions, respectively, 
against the first 21 nucleotides starting from the 5 1 start 
of translation in the mRNAs for uPA and CL, respectively. 
The sense-uPA was made in the sense direction from the start 
of translation of the uPA mRNA and was used as a control 
oligo. In initial experiments NIH/3T3, EJ-vHa-ras- and 
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RASlLeudel-transformed cells were seeded 50,000 cells per 
=-------
well in a 24 well Petri dish (Flow Lab) and incubated for 24 
hr in media containing 10% heated-inactivated FBS (HI-FBS). 
The medium was changed to media containing an 
oligonucleotide and incubated for 24 h. Anti-CL and anti-uPA 
were used at concentration of 10 uM, 50 uM, 100 uM and 200 
uM, 0.3 ml/per well. The wells were washed 3 x with serum-
free media, 0.5 ml of serum-free media added to each well 
and conditioned media removed every 12 hr, up to for 48 hr. 
The conditioned media was centrifuged at 10,000 rpm 
(Beckman) in 1.5 ml microcentrifuge tubes and saved at -20 
0c until assayed. 
Lung Colonization Assay 
The murine lung colonization assay was performed in a 
similar manner as previously described (Bradley et al., 
1986). The semiconfluent cells were harvested by adding 0.1% 
trypsin and 1 mM EDTA in PBS and the cells were quickly 
removed from trypsin in complete medium, centrifuged at 500 
x g, and resuspended in PBS (no calcium or magnesium). Cells 
were counted in a Coulter counter, and diluted to 1,500,000 
cells/ml. Cells were maintained on ice prior to injection. 
Athymic female nude mice (Ncr nu/nu) were obtained from NIH-
Frederick Facility and housed in the Loyola Medical Center 
Animal Care Facility in sterile cages for 1 week prior to 
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use. The mice used in the experiment were 4-5 weeks of age 
at the time of injection. A 0.2-ml cell suspension (300,000 
cells/mouse) was slowly injected into the lateral tail vein 
with a 26-gauge needle. The injection schedule was 
alternated between animals in the control group and animals 
in the experimental group, to minimize experimental 
variances, especially time. At end of injection, cell 
viability was determined by the trypan blue dye exclusion 
test (Phillips, 1973) assay. Viable cells ranged 91-97% 
under the experimental conditions. 
The mice were maintained under sterile barrier 
conditions and sacrificed 14 days after tail vein injection, 
the lungs were removed, and the animal were examined for 
disseminated tumor colonies. Lungs were fixed in Bouin's 
solution and the number of surf ace colonies were counted 
under a dissecting microscope. 
Polyacrylamide Gel Electrophoresis 
Discontinuous sodium dodecyl sulfate polyacrylamide 
gel electrophoresis was performed to verify the induced 
proteins in Western blots after phorbol ester stimulation of 
the cell lines. The procedure was that of Laemmli (1970) as 
detailed by Davis et al. (1986). All electrophoresis 
equipment and reagents were from Bio-Rad (Richmond, CA). 
Gels were 16 X 18 X 0.75 cm thick and are composed of a 
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stacking gel (4-5 cm) of 3% acrylamide and a resolving gel 
of 11% acrylamide. Electrophoresis was performed at 10 mA 
for overnight in a running buffer of 0.025 M Tris, 0.192 M 
glycine (pH 8.3) containing 1% sos. The lower gel buffer was 
o.5 M Tris pH 6.3 containing 1.5 M Tris (pH 8.8) and 0.4% 
sos. The stacking gel buffer was 0.5 M Tris, pH 6.3, 
containing 0.4% sos. Samples for electrophoresis were 
diluted 1:1 in sample buffer (10 ml glycerol, 23 ml of 10% 
sos, 2 ml of 1% bromphenol blue, 8.3 ml stacking gel buffer 
and 6.7 ml H20). 
Western Blot 
Western blot analysis was used to detect increased 
amount of protein after phorbol ester stimulation. 
Polyclonal antibodies against human PAI-2 and urokinase were 
purchased from American Oiagnostica Inc. (New York, NY). The 
cells were grown in 6-well cell culture cluster dish (GIBCO, 
Grand Island, NY) to subconfluence. Culture media (1 ml) 
containing 20 nM PMA and 10% HI-FBS were added into the 
flasks. The media were collected and the attached cells were 
lysed with 0.2 ml of solution containing 1% sos and 1 mM 
EOTA. The lysed cells were mixed with the collected culture 
media and saved at -20°C until assayed. The protein 
concentrations were determined by the BCA protein assay 
method (Pierce Chemical Company, Rockford, Ill.). The 
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procedure for SDS-polyacrylamide gel electrophoresis was the 
same as that described as above. Ten mg of the protein 
sample were loaded into each well. After electrophoresis, 
the protein were transferred to a nitrocellulose filter 
(Bio-Rad, Richmond, CA) with an electrophoretic transfer 
apparatus (Bio-Rad) in a transfer buffer containing 0.05 M 
Tris, 0.2 M NaCl, 0.05% Tween and 1% bovine serum albumin 
(TBST buffer) for overnight at 4°C to block any non-specific 
binding sites, washed for 30 min with TBST twice, and then 
incubated with mouse anti-human antibody (American 
Diagnostica Inc. New York, NY) at a concentration of 5 ug/ml 
for 2 hr. Nonspecifically bound antibody was removed by 
washing the filter with TBS 3 times. Biotinylated goat anti-
mouse IgG (BRL) was next added at a concentration of 1.5 
ug/ml in TBST. Bound antibody was detected with avidin 
conjugated to horse-radish peroxidase (Avidin-HRP) and 
BCIP/NBT (5-bromo-4-chloro-3-indoylphosphate/nitroblue 
tetrazolium) as the substrate in carbonate buffer (0.1 N 
NaHC03 , 10 mM MgC12 , pH 9.8) was added for color 
development. 
Preparation of Cultured Media from organ Fragments of 
Nude Mice 
The procedure for the collection of conditioned media 
from organ culture was the similar to that described by 
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(Price et al., 1988). Female bale mice (5-6 weeks) were 
purchased from NCI-Frederick Facility and housed in the 
Loyola Medical Center Animal Care Facility in sterile cages 
for 1 week prior to use. The mice were sacrificed by 
exposure to ether, and their lungs, kidneys and spleens were 
detached. The organs were rinsed with the medium, and fatty 
tissue was removed. The organs were cut with a razor blade 
into 1-2 mm3 pieces, washed 3 times with cold RMPI 1640 
culture medium, and the pieces were incubated in cell 
culture dishes with 10 ml of RMPI 1640 at 37 c with 1% fetal 
bovine serum for 6 hours, and replaced with 10 ml of fresh 
media containing 10 % HI-FBS (Flow Lab). The media were 
collected after 24 hr, and centrifuged at 500 x g to remove 
debris. 
CHAPTER IV RESULTS 
1 • Expression of Mouse Urokinase mRNA in NIH 3T3 Fibroblasts 
and ras oncogene Transformed NIH 3T3 Cell Lines with 
Phorbol Ester (PMA) Treatment. 
The NIH 3T3 cell lines transformed by the oncogenes 
Leu Leu EJ-ras, EJ/vHA-ras, HYB c and RASl del have been 
previously described (Bradley et al., 1986). EJ-ras contains 
an activating Gly to Val mutation at codon 12 and was 
originally isolated from a human carcinoma (Capon et al., 
1983). The EJ/vHA-ras is a chimeric construct (Gibbs et al., 
1984), which combines the first 22 amino acid codons of 
EJ-ras and the remaining COOH-end amino acids from the viral 
v-Ha-ras gene. EJ/vHA-ras has two activating mutations, at 
Leu Leu 
codons 12 and 59. HYB C and RASl del are two yeast RASl 
containing sequences used to transform the NIH 3T3 cells 
(Defoe-Jones et al., 1985). The HYB CLeu gene contains the 
yeast RASl sequences 1 to 161 joined to amino acids 154 to 
189 from the v-Ha-ras sequence with residue 68 mutated to 
Leu. Amino acid 68 is structurally analogous to amino acid 
61 in the mammalian Ha-ras protein sequence (Table 4). The 
RASlLeudel contains all yeast RASl sequences and was prepared 
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by deleting amino acid codons 186 through 302 of RASl and 
then ligating to codon 186 the COCH-terminal codons for 
residues 303 to 309 in the RASl sequence which provide the 
cys-a-a-X sequence required for farnesylation and membrane 
association (Hancock, et al., 1989). The sequence also 
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contains the activating Leu mutation at amino acid position 
68 (analogous to position 61 in the Ha-ras protein sequence, 
Table 4). These activated mammalian ras and yeast RAS genes 
transform NIH 3T3 fibroblasts into cells which are 
tumorigenic and metastatic in nude mice (Bradley et al., 
1986) • The ras-transformed cells do not show a correlation 
of metastatic ability with the amount of activated Ras 
protein present (Bradley et al., 1986). Of the Ras 
Leu transformed cells, the EJ/vHa-ras and the RASl del 
transformations appear most malignant, each giving a 9- to 
10-f old greater number of lung colonies than the other 
Leu 
activated Ras transformed cell lines (EJ-ras and HYB C -ras 
) when tail vein injected into nude mice (Bradley et al., 
1986). The prior results of Bradley on the nude mice assay 
of these ras-transformed cells are summarized in Table 1. 
To study the correlation between mouse urokinase 
expression and tumor metastatic potentials, the RNAs were 
isolated from untransformed NIH 3T3 fibroblast and the four 
different ras oncogene transformed mouse cell lines, under 
subconfluent conditions. A slot blot analysis was carried 
out to study relative amount of uPA mRNA among these cell 
lines. The results are shown on Figure 1. The highly 
malignant EJ/vHa-ras-transformed cells show a high 
constitutive level of uPA mRNA over NIH 3T3 controls and 
other ras oncogene-transformed cells, (see zero hour time 
point in Figure 1). However, the highly malignant 
RAS110udel-transformed cells show low levels of uPA mRNA, 
similar to control NIH 3T3 cells. 
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Tumor cells may change phenotype in the different 
steps of metastasis. The change, if it occurs, may be 
related to environmental signal factors near each of the 
step barriers. A highly metastatic tumor cell in this 
paradigm, is characterized by its facile ability to change 
its phenotype in response to environmental signal factors. 
As it is currently impossible to study how the protease 
activities are actually regulated in vivo by signal factors, 
I tried to obtain support for this idea by adding a tumor 
promoter, the phorbol ester, phorbol-12-myristate-13-acetate 
(PMA or TPA), into cell culture. While phorbol ester is not 
a naturally occurring signal factor, it activates protein 
kinase C (PKC) which is a part of the inositol phosphate 
signal transduction pathway (O'Brian and Ward, 1988; 
Weinstein, 1988; Blumer, 1988). This is one of the major 
pathways by which extracellular signals are transmitted 
intracellularly, and thus may mimic natural signals that a 
tumor cell could encounter in the metastatic process. 
Figure 1 then also shows the changes in steady-state 
{EJ-ras} 
{EJ/vHa-ras} 
{c-Ha-ras} 
{Hyb C} 
{RASl-del} 
{EJ-ras} 
{EJ/vHa-ras} 
{c-Ha-ll§} 
{Hyb C} 
{RASl-del} 
{EJ-ras} 
{EJ/vHa-ras} 
{c-Ha-ras} 
{Hyb C} 
{RASl-del} 
{EJ-ras} 
{EJ/vHa-ras} 
{c-Ha-ras} 
{Hyb C} 
{RASl-del} 
Table 4. Alignment of Ras Sequencesa 
Jb *d 
.....•• MTE YKLVVVGAvG 
....... MTE YKLVVVGAvG 
.•..••. MTE YKLVVVGAGG 
MQGNKSTirE 
MSGNKSTirE 
1 
44 
YKiVVVGgGG 
YKiVVVGgGG 
* * 
VGKSALTIQL 
VGKSALTIQL 
VGKSALTIQL 
VGKSALTIQF 
VGKSALTIQF 
IQNHFVDEYD 
IQNHFVDEYD 
IQNHFVDEYD 
IQsyFVDEYD 
IQsyFVDEYD 
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PTIEDSYRKQ 
PTIEDSYRKQ 
PTIEDSYRKQ 
PTIEDSYRKQ 
PTIEDSYRKQ 
50 
93 
VVIDGETCLL DILDTAGQEE YSAMRDQYMR TGEGFLCVFA INNTKSFEDI 
VVIDGETCLL DILDTtGQEE YSAMRDQYMR TGEGFLCVFA INNTKSFEDI 
VVIDGETCLL DILDTAGQEE YSAMRDQYMR TGEGFLCVFA INNTKSFEDI 
VVIDdkvsiL DILDTAGLEE YSAMREQYMR TGEGFLlVYs VtsrnSFDEl 
VVIDdkvsiL DILDTAGLEE YSAMREQYMR TGEGFLlVYs VtsrnSFDEl 
51 100 
94 142 
HQYREQIKRV KDSDDVPMVL VGNKCDLA.A RTVESRQAQD LARSYGIPYI 
HQYREQIKRV KDSDDVPMVL VGNKCDLA.A RTVESRQAQD LARSYGIPYI 
HQYREQIKRV KDSDDVPMVL VGNKCDLA.A RTVESRQAQD LARSYGIPYI 
lsYyqQiqRV KDSDyIPvVv VGNKlDLeNe RqVsyedglr LAkqlnaPFl 
lsYyqQiqRV KDSDyIPvVv VGNKlDLeNe RqVsyedglr LAkqlnaPFl 
101 150 
143 189 
ETSAKTRQGV EDAFYTLVRE IRQH •• KLRK LNPPDESGPG CMSCKgVLS* 
ETSAKTRQGV EDAFYTLVRE IRQH •• KLRK LNPPDESGPG CMSCKgVLS* 
ETSAKTRQGV EDAFYTLVRE IRQH •• KLRK LNPPDESGPG CMSCKgVLS* 
ETSAKqainV DDAFYTLVRE IRQH .• KLRK LNPPDESGPG CMSCKgVLS* 
ETSAKqainV DEAFYsLIRl VRddggKyns MNrqlDgGcQ iic* .•.•.• 
151 193 
---------------------------------------------------------------------------
Ul 
-....] 
aAlignmentmade by the PILEUP alogrithms in Genetics Computer Group Software 
[Devereux, J., Haeberli, P., Smithies, o. (1984) Nucleic Acids Research 12, 387-
395], using default settings. Upper case letters show consensus between three or more 
sequences. Sequences utilized from the GenBank and EMBL data bases are human 
c-Ha-ras-1 [accession number J00277] for c-Ha-ras, murine Sarcoma virus 
{Harvey-strain) H-ras gene [accession number X00740] for v-Ha-ras, and yeast 
{Saccharomyces cerevisiae) I:B..§_-H related gene c-ras-sc-1 [accession number X00527] 
for RASl. Cell lines containing the constructs were previously prepared and 
reported by Bradley et al.{1986). 
bNumbering based on sequence of EJ-ras. 
cNumbering based on sequence of RASlLeudelprotein. 
dAsterisk (*) on top of line designates point of activating mutation in one or more 
of the sequences. Underlined Cys near COCH-terminal end shows potential farnesylation 
site. 
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Fiqure 1. Slot Blot Analysis of Mouse urokinase mRNA Levels 
from NIH 3T3 Fibroblasts and ras oncoqene Transformed NIH 
3T3 cell Lines. 
The cells were treated with PMA (20 nM) for the 
designated times, prior to total RNA extraction. The RNAs 
were immobilized on a Zeta-probe filter and hybridized with 
32p-labeled mouse urokinase cDNA. Washed filter was exposed 
to X-ray film. 
09 
concentrations of uPA mRNA in mouse NIH 3T3 and the ras 
oncogene-transformed cells treated with 20 nM of PMA, for 
the time periods indicated. On PMA treatment, increases in 
uPA mRNA levels occur in the EJ/vHa-ras and EJ-ras 
transformed cells as well as the untransformed NIH 3T3 
61 
cells. In contrast, the normal PMA induction of uPA was 
suppressed in cells transformed by the RASl Leudel and the HYB 
cLeu yeast ras genes. 
The same RNA filter used in Figure 1 was rinsed and 
rehybridized with a Drosophila actin probe. The filters 
obtained with mouse urokinase and actin probes were traced 
with a densitometer. The densitometer trace was normalized 
to the actin mRNA control. Table 5 shows the average values 
for uPA mRNA levels from 4 different experiments. In EJ/vHa-
ras cells the uPA mRNA levels are 5.4-fold higher than NIH 
3T3 cells with a standard deviation 1.7 at O hr PMA 
treatment. The uPA mRNA of other ras transformed cell lines 
at o hr PMA treatment have similar amounts within 
experimental error of uPA mRNA as NIH 3T3. 
With PMA treatment, uPA mRNA showed a 6-fold 
induction in NIH 3T3 cells and a 2- to 3-fold induction in 
both EJ-ras and EJ/vHa-ras transformed cells at 8 hours. No 
induction was observed in the yeast ras transformed lines 
L~ ~u , HYB c and the RASl del lines. 
2 • sxpression of mouse cathepsin L mRNA in NIH 3T3 
Fibroblasts and ras Oncogene Transformed NIH 3T3 Cell 
Lines with Phorbol Ester (PMA) Treatment. 
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As CL was previously reported to be highly expressed 
in transformed cells {Gottesman, 1988), I applied a similar 
strategy as above to study the CL mRNA expression in the ras 
transformed cell lines. Figure 2 shows mRNA levels for CL in 
NIH 3T3 and ras transformed cell lines treated with PMA for 
the times indicated. Strikingly, only in the highly 
Leu 
malignant .RASl del transformed cells are the CL mRNA 
constitutively expressed at high steady-state 
concentrations; while in the EJ-ras and EJ/vHa-ras cells the 
levels are close to one of control NIH 3T3 cells 
(constitutive levels are observed at the zero time points). 
In addition, Figure 2 shows that the CL mRNA levels are 
strongly induced by 20 nM PMA only in the yeast 
Leu Leu Leu RASl -transformed cells (HYB C or RASl del genes cell 
lines). CL is clearly not induced by 20 nM PMA in the cells 
transformed by the EJ/vHa-ras, EJ-ras, or in untransformed 
NIH 3T3 cells. 
The same RNA filter used in Figure 2 was rinsed and 
rehybridized with the Drosophila actin probe. Densitometer 
traces were normalized to the actin mRNA controls. The 
experiments were run 4 times, average values of 4 
independent experiments with standard deviation are 
Figure 2. Slot Blot Analysis of Mouse cathepsin L mRNA 
Levels in NIH 3T3 Fibroblast and ras Oncogenes Transformed 
NIH 3T3 Cell Lines. 
The cells were treated with PMA (20 nM) for the 
designated time, the total RNAs were extracted, the RNAs 
immobilized on a Zeta-probe filter, hybridized with 32P-
labeled mouse cathepsin L cDNA probe, and exposed to X-ray 
film. 
63 
51 
!· 
(') 
r-
I N 
.. 
en 
w 
N 
64 
Table s. Levels of uPA mRNA among ras oncogene-transformed Mouse Fibroblasts 
Treated with PMA and Normalized with Actina 
Hours PMA Treatment 0 2 4 8 16 32 
------------------------------------------------------------------------------------
NIH/3T3 1.0(0.3) b 3.5(0.1) 5.4(1.5) 5.5(2.1} 4.2(1.8) 2.0(0.7) 
EJ-ras 1.0(0.1) 1.9(0.3) 3.2(2.1) 2.7(1.2) 2.4(0.6) 1.2(0.7) 
EJ/vHA-ras 5.4(1.7) 8.9(0.7) 11.5(1.7) 12.9(2.8) 10.0(4.4) 6.6(2.3) 
HYB CLeu 0.9(0.3) 1.0(0.2) 1.0(0.2) 1.1(0.1) 1.4(0.4) 0.9(0.3) 
RAS110udel 1.3(0.4) 1.1(0.1) 1.2(0.4) 1.2(0.2) 1.2(0.3) 1.3(0.3) 
8
mRNAs of the cell lines were determined by slot blots analysis of total RNA (5 
ug/per slot). Following autoradiography, the intensities of the slot signals were 
quantified by densitometry. The results were normalized to actin, which was 
hybridized and densitometrized with the same filter. The numbers are the average of 4 
separate runs and standard deviation is in bracket. 
bUnit is densitometeric value. 
Figure 3. Slot Blot Analysis of Mouse cathepsin B mRNA 
Levels in NIH 3T3 Fibroblast and ras oncogenes Transformed 
NIH 3T3 Cell Lines. 
The cells were treated with PMA (20 nM) for the 
designated times, total RNAs were extracted, the RNAs were 
immobilized on Zeta-probe filter, hybridized with 32p-
labeled mouse cathepsin B cDNA probe, and exposed to X-ray 
film. 
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Table 6. Levels of CL mRNA among ras oncogene-transformed Mouse Fibroblasts 
Treated with PMA and Normalized with Actina 
Hours PMA Treatment o 2 4 8 16 32 
-------------------------------------------------------------------------------------
NIH/3T3 1.4(0.1) 1.4{0.1) 1.5(0.2) 1.2(0.1) 1.3(0.2) 1.1(0.1) 
EJ-ras 3.5(0.3) 3.1(0.3) 3.2(0.5) 3.2(0.3) 3.3(0.3) 3.1(0.2) 
EJ/vHA-ras 1.8(0.4) 1.6(0.3) 1.5(0.7) 1.5(0.3) 1.6(0.4) 1.8(0.6) 
HYB CLeu 1.1(0.2) 2.8(0.6) 3.4(1.3) 3.1(1.0) 1.3(0.1) 1.1(0.4) 
RASlLeudel 6.1(1.1) 14.8(4.2) 12.4(4.9) 16.8(1.2) 15.0(2.7) 14.7(4.0) 
amRNAs of the cell lines were determined by slot blots analysis of total RNA (5 
ug/per slot). Following autoradiography, the intensities of the slot signals were 
quantified by densitometry. The results were normalized to actin, which was 
hybridized and densitometrized with the same filter. The numbers are the average of 4 
separate runs and standard deviation is in bracket. 
bunit is densitometeric value. 
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displayed in Table 6. The data show that CL mRNA levels are 
6 .1-fold (standard deviation 1.1) greater in RASlLeudel cells 
than NIH 3T3 cells. The other transformed cell lines show 
the 1.1 to 3.5-fold higher CL mRNA level than NIH 3T3 cells. 
The data also show the increase of induction of CL mRNA by 
PMA was 2.5- to 3.2-fold in HYB CLeu and 2- to 3-fold in 
RASlLeudel at 8 hours. No apparent inductions with PMA were 
observed in the EJ/vHa-ras, EJ-ras or NIH 3T3 cells. 
3. Expression of Mouse cathepsin B mRNA in NIH 3T3 
Fibroblasts and ras Oncogene Transformed NIH 3T3 Cell 
Lines with Phorbol Ester (PMA) Treatment. 
Figure 3 shows the changes in CB mRNA steady-state 
concentrations under conditions of 20 nM PMA stimulation. 
The changes in CB mRNA are in-between the patterns observed 
for CL and uPA mRNAs. Constitutively higher levels of CB 
mRNA are observed in both mammalian-like EJ-ras and 
EJ/vHa-ras, and in yeast-like RASlLeudel transformed cells. 
However, neither PMA induction of CB mRNA was observed in 
the transformed EJ-ras cells, nor is PMA induction observed 
in the untransformed NIH 3T3 controls. The same RNAs filter 
was rehybridized with the Drosophila actin probe. 
Densitometer traces normalized to the actin mRNA controls 
and averaged over 4 independent experiments (Table 7) show 
that a 2-f old increase CB mRNA is observed at 4 hours of PMA 
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riqure 4. Slot Blot Analysis of Mouse Protease mRNAs Levels 
from NIH 3T3 Fibroblast and ras oncogenes Transformed NIH 
lT3 cell Lines after Serial Dilutions. 
Total RNAs were extracted from NIH 3T3 cell and four 
cell lines transfected with different ras oncogenes without 
PMA stimulation. The RNAs were serially diluted and 
immobilized on a Zeta-probe filter and hybridized with 32P-
labeled mouse urokinase, cathepsin L, B and Drosophila cDNA 
actin probes, and exposed to X-ray film to different times. 
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Table 7. Levels of CB mRNA among ras Oncogene-transformed Mouse Fibrob1asts 
Treated with PMA and Normalized with Actina 
Hours PMA Treatment o 2 4 8 16 32 
------------------------------------------------------------------------------------
NIH/3T3 2.8(0.5) 3.2(0.3) 3.5(0.6) 3.3(0.3) 2.9(0.3) 2.6(0.5) 
EJ-ras 7.8(0.2) 6.8(1.6) 6.6(0.6) 6.5(0.3) 3.3(0.3) 3.1(0.2) 
EJ/vHA-Il.§_ 5.4(0.3) 12.5(2.0) 12.8(2.4) 9.8(0.7) 8.5(0.8) 5.9(1.0) 
HYB CLeu 2.4(0.1) 10.3(3.7) 9.9(2.7) 10.2(0.4) 3.6(0.1) 1.1(0.4) 
RASlLeudel 4.2(0.3) 12.8(9.4) 12. 1 ( 5. 0) 12.3(1.1) 11. 0 (2. 5) 6.3(2.8) 
8
mRNAs of the cell lines were determined by slot blots analysis of total RNA (5 
ug/per slot). Following autoradiography, the intensities of the slot signals were 
quantified by densitometry. The results were normalized to actin, which was 
hybridized and densitometrized with the same filter. The numbers are the average of 4 
separate runs and standard deviation is in bracket. 
bUnit is densitometeric value. 
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stimulation in cells transformed with 
mammalian-likeEJ/vHA-ras and the increase persisted for upto 
s hours. CB mRNA concentration increased 4-fold at between 2 
Leu 
and 8 hours after PMA stimulation in HYB C transformed 
cells and 3-fold during that same period in RASlLeudel 
transformed cells. 
To order to demonstrate that conclusions from the 
slot blots above are not caused by over-saturating the 
filter membrane, the RNA samples (without PMA stimulation) 
were serially diluted from 1 to 4 ug per slot. The filters 
were hybridized with the cDNA probes under the identical 
conditions as above. The results are shown in Figure 4. Just 
as previously described, the highly malignant 
EJ/vHa-ras-transformed cells show a higher constitutive 
level of uPA mRNA over NIH 3T3 controls and other ras 
oncogene-transformed cells. The CL mRNA is constitutively 
expressed at the highest steady-state concentrations in the 
highly malignant RASlLeudel transformed cells. Densitometer 
analysis of the blots confirms the relative concentrations 
previously described. 
To further confirm the results of the slot blots for 
CL, Northern blots were carried out. The Northern not only 
compares the concentrations of mRNAs, but also demonstrates 
the molecular weights of the mRNAs. Cytoplasmic RNAs were 
isolated from cell cultures without PMA treatment, and the 
poly(A)+ mRNAs were obtained with a poly(dT) column. The 
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Figure s. Northern Blot Analysis of Mouse Cathepsin L mRNA 
Levels from NIH 3T3 Fibroblast and ras Oncogenes Transformed 
NIB 3T3 Cell Lines. 
+ Poly(A) mRNAs were extracted from NIH 3T3 cell and 
four other cell lines transfected with different ras 
oncogenes. The RNAs were separated by electrophoresis 
through 1% agarose gel. The RNAs were transferred onto zeta-
probe filter, hybridized with 32P-labeled mouse cathepsin L 
cDNA probe (top) or GAPD (bottom), and exposed to X-ray 
film. 
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mRNAS were separated by electrophoresis through a 1% agarose 
gel . The RNAs were transferred onto a Zeta-Probe filter and 
hybridized with a 32P-labeled mouse cathepsin L cDNA probe. 
The result is displayed on Figure 5. In this figure, only 
the RAS11eudel transformed cells show highest expression 
among the other cell lines. Other observations are also 
consistent with those obtained in the slot blot analyses, 
described above. The molecular weight of the CL mRNA blotted 
is 1.8 to 2.0 kilobase (kb), which is consistent with the 
literature (Troen et al., 1987). 
4. comparison of Transcription Rates of uPA, CB and CL 
with and without PMA stimulation in NIH 3T3 
Fibroblasts and ras oncogene Transformed NIH 3T3 Cell 
Lines 
The induction of the protease mRNA levels could be 
the result of either increases in transcription rates or 
decreases in mRNA degradation rates. In order to further 
investigate the mechanism of induction, run-on assays were 
carried out. The nuclei of the cell were isolated from the 
cells in culture either with 20 nM PMA for 2 hours or 
without PMA treatment. The nuclei were incubated with 32P-
UTP. The labeled RNAs were isolated and hybridized to the 
protease cDNA plasmids immobilized on a nitrocellulose 
filter. The filters were washed and exposed to X-ray film. 
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The results are displayed on Figure 6. Of the 3 cell lines 
studied, the CL gene transcription rate shows a much higher 
transcription rate and PMA inducibility only in the yeast 
RASl Leudel transformed cells. PMA stimulation of CL 
=-
transcription is not observed in the EJ/vHA-ras transformed 
or untransformed NIH 3T3 fibroblasts. CB transcription rates 
show a mild increase in both the RASl Leudel transformed cells 
and the EJ/vHA-ras transformed cells on PMA stimulation, but 
shows no PMA stimulation in the untransformed NIH 3T3 cells. 
The transcription rate of the uPA gene is higher in the 
EJ/vHa-ras transformed cell than the NIH 3T3 cells, uPA gene 
transcription rate in the RASl Leudel cells is not 
significantly different from one in NIH 3T3. In addition, 
PMA shows a significant increase in uPA gene transcription 
in the untransformed NIH 3T3 cells and in the EJ/vHA-ras 
transformed cells, but no PMA stimulation of transcription 
Leu 
rate is observed in the RASl del-transformed 
cells. 
Results from the densitometer traces of the run-on 
assays are shown on Table 8. The data shows that the CL gene 
transcription rate in RASlLeudel cells was 6-fold greater 
than in NIH 3T3 cells, and PMA causes a further 2-fold 
increase of CL gene transcription rates was observed in 
Leu RASl del-transformed cells. CL transcription rate are not 
PMA stimulated in NIH/3T3 or EJ/vHa-ras-transformed 
cells.The uPA transcription rate was 7-fold higher in 
riqure 6. The Run-on Assays of uPA, CB and CL with and 
without PMA Stimulation in NIH 3T3 cells, EJ/vHa-ras and 
~lL~del-transformed Cells. 
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The nuclei were isolated from the cell cultures with 
pMA treatment (20 nM, 2 hours) or without PMA treatment. 
Nuclei were incubated with 32P-UTP, and RNAs were isolated, 
and hybridized to the cDNAs for uPA, CB and CL immobilized 
on a nitrocellulose paper. The filters were washed and 
exposed to X-ray film. 
CL 
CB 
UK 
..... 
CL 
CB 
UK 
llClin 
GENE 
CL 
CB 
uPA 
ACT IN 
TABLE 8 Relative mRNA Transcription Rates 
by Run-on Assay• 
A. No PMA treatment 
CELL LINES 
ASSAYED NIH/3T3 EJ/vHA-ras RAS 1 L8'1>EL 
0.89 2.38 5.24 
0.86 0.91 1.61 
0.10 0.72 0.13 
0.31 0.33 0.30 
B. Treatment with PMA (20 nM) for 2 hours 
CELL LINES 
GENE ASSAYED NIH/3T3 EJ/vHA-ras RAS1Le~EL 
CL 0.93 2.02 9.61 
CB 0.90 1.81 2.70 
uPA 0.39 2.75 0.15 
ACT IN 0.28 0.35 0.29 
'Values from desitometer trace of autoradiography. 
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EJ/vHa-ras-transformed cells than in untransformed NIH 3T3 
cell. PMA treatment caused a further 4-fold stimulation of 
transcription rate in untransformed NIH 3T3 cells and in 
EJ/vHa-ras-transformed cells. The uPA gene transcription 
Leu 
rate was not elevated in the RASl del cell nor was uPA 
transcription stimulated by PMA in this cell line. The 
results of the run-on assays mimic the changes observed in 
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steady-state mRNA concentrations in Figures 1, 2 and 3, and 
demonstrate that the differences observed in the 
constitutive steady-state mRNA levels and with PMA 
stimulation for the different ras-transf ormations are 
primarily due to increases in transcription rates and not to 
differences in mRNA stability. 
s. Determination of uPA Enzymatic Activities of conditioned 
Media from NIH 3T3 Fibroblasts and ras oncogene 
Transformed NIH 3T3 Cell Lines Treated with 
Oligonucleotides 
Based on the observation that uPA mRNA is highly 
expressed in the cells transformed with the EJ/vHA-ras, 
while cathepsin L mRNA is highly expressed in the cells 
transformed with RASlLeudel gene, it would be of interest to 
test the possibility of different involvements of uPA and CL 
in a metastatic assay. 
Anti-sense oligodeoxynucleotides are short synthetic 
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nucleotide sequences formulated to be complementary to a 
specific gene or RNA message. Through the binding of these 
oligomers to a target sequence in a cell, transcription or 
translation of the gene can be selectively blocked. A number 
of studies were completed with oligodeoxynucleotides 
(reviewed by Rothenberg et al., 1989), which suggests that 
antisense deoxyoligonucleotide inhibitors may be also able 
to selectively inhibit the urokinase and CL gene expressions 
in the ras oncogenes transformed cell lines. If antisense 
oligonucleotide could inhibit CL and uPA gene expressions, 
then the cells could be then injected into nude mice to 
determine the effect of selectively inhibiting uPA and CL 
gene expressions on experimental metastasis. 
Three 21-mer oligonucleotides used in this work were 
sense-uPA (5'-ATGAAAGTCTGGCTGGCGAGC-3'), anti-uPA (5'-
GCTCGCCAGCCAGACTTTCAT-3'), and anti-CL (5'-
CAAAAGGAGTAAAAGATTCAT-3'). The optimum concentration to 
achieve the maximal inhibition was determined by varying the 
concentration of the oligo. The secretion of uPA and CL 
activity into the cell culture medium after removal of these 
oligonucleotide inhibitors were quantified by chromogenic or 
fluorogenic substrate assays (discussed in the following 
paragraphs). A concentration of 10, 20, 50, 100, 200 uM was 
tested for each of the antisense oligonucleotides, and the 
optimum concentration to achieve the maximal inhibition was 
found to be 100 uM for both ant-uPA and anti-CL (Table 9). 
This concentration was the one used in the following 
inhibitory studies with these oligos. 
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The secretion of uPA activity into the cell culture 
medium after removal of the oligonucleotide inhibitors was 
quantified by measuring plasmin activities following the 
activation of plasminogen to plasmin by the urokinase. Cells 
were plated into wells and incubated in complete media 
containing 10% FBS and the different oligos (100 uM) for 24 
hr as described in methods. The media was removed. The cells 
were then incubated in serum-free, oligo-free media. This 
medium was replaced every 12 hrs for upto 48 hrs. The media 
samples were assayed for secreted uPA enzyme activity. 
Figure 7 is a demonstration of uPA activities of 
these cell lines treated with three oligos. EJ/vHa-ras has 
the highest uPA enzymatic activity of these cell lines. 
Anti-uPA inhibited secreted activity by approximately 45% in 
all cell lines. The inhibition lasted for at least 48 hours 
after removal of the antisense oligo from the media. uPA 
sense oligo has no obvious effect on the uPA enzymatic 
activities of these cell lines. 
Table 10 gives the numbers plotted in Figure 8 and 
shows that without the oligonucleotide inhibitor, NIH 3T3 
cells displayed a uPA enzymatic activity corresponding to an 
absorbance 1.36 per hour per 106 cells for the first 12 
hours. This is equal to the activity level of RASlLeudel, 
whereas EJ/vHA-ras cells showed about a 3-fold higher uPA 
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Fiqure 1. uPA Enzymatic Activities of conditioned Media from 
NIH 3T3 Fibroblasts and ras oncogene Transformed NIH 3T3 
cell Lines on Treatment with Oligodeoxynucleoti~es. 
Cells were plated into wells and incubated in 
complete media containing 10% FBS and oligo (100 uM) for 24 
hr. The media was removed and the cells were incubated in 
serum-free, oligo-free media which was removed from cells 
every 12 hrs up to 48 hrs and assayed for secreted enzyme 
activity. 
Asterisk (*) on the top of the bars designated 
specific condition with significant difference from the 
control group (no oligo treatment). 
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enzymatic activity. The difference in activity levels are in 
the direction expected from their respective mRNA levels and 
gene transcription rates, previously determined. Treatment 
with sense-uPA oligo caused no apparent change in uPA 
enzymatic activities in these cell lines studied. 
6. Determination of CL Enzymatic Activities of Conditioned 
Media from Mouse NIH 3T3 Fibroblast and ras oncogene 
Transformed NIH 3T3 Cell Lines Treated with 
Oligonucleotides. 
CL enzymatic activities were determined against the 
substrate N-carbobenzoxy-L-Phe-L-Arg-7-aminomethylcoumarin 
(Z-Phe-Arg-AMC) • Total enzymatic activity was first 
determined both in secreted medium and in membrane 
associated components. The results are shown in Table 11. As 
the results show the cells-associated activity is only 11-25 
% of total enzymatic activities, the following assays to 
test inhibitory activities of the oligonucleotide antisense 
were carried out only on the secreted medium. 
The results are displayed in Figure 8. Obviously, 
RA Leu 
__Ql del cells has the highest CL enzymatic activity among 
the cell lines. Anti-CL inhibited secreted activities by 
about 35% in all cell lines, and its inhibitory effect 
lasted for 24 hours after removal of the antisense oligo. 
UPA sense oligo has no noticeable effect on the CL enzymatic 
Table 9. concentration Dependence of Oligonucleotides 
Inhibitory Effects8 
anti-uPA concentration 
no oligo 
10 uM 
20 uM 
50 uM 
100 uM 
200 uM 
EJ-vHa-ras Cells 
uPA activity 
4. ab co. 9) 0 
4.6 (1.0) 
4.2 (0.9) 
3.7 (0.8) 
2.7 (0.7) 
2.6 (0.5) 
% inhibition 
10 
13 
23 
44 
45 
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-----------------------------------------------------------
anti-CL concentration 
no oligo 
10 uM 
20 uM 
50 uM 
100 uM 
200 uM 
RASl Leudel Cells 
CL activity 
78.2d (15.2) 
75.4 (15.7) 
71.3 (13.8) 
58. 6 ( 11. 4) 
50.8 (9.9) 
51.3 (11.1) 
% inhibition 
4 
9 
25 
35 
34 
8 Enzymatic activities were determined with the first 12 hour 
serum-free medium after removal of the oligo inhibitors. 
buPA enzymatic activities were determined with the chromogenic 
substrate S-2551. Numbers are the average of 3 separate runs 
with units of O.D. per 106 cells per hour 
0The number in bracket is standard deviation. 
d CL enzymatic activities were determined by substrate N-
carbobenzoxy-L-Phe-L-Arg-7-aminomethylcoumarin (Z-Phe-Arg-
AMC) with units of pmol/min/106 cells. 
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riqure s. Cathepsin L Enzymatic Activities of Conditioned 
Media from NIH 3T3 Fibroblasts and ras Oncogene Transformed 
NIH 3T3 Cell Lines on Treatment with Oliqodeoxynucleotides. 
Cells were plated into wells and incubated in 
complete media containing 10% HI-FBS and oligo (100 uM) for 
24 hr. The media was removed and the cells were incubated in 
serum-free, oligo-free media which was removed from cells 
every 12 hours up to 48 hours and assayed for the secreted 
enzyme activity. 
Asterisk (*) on the top of the bars designated 
specific condition with significant difference from the 
control group (no oligo treatment). 
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activities of these cell lines under the experimental 
conditions. 
The values plotted in Figure 8 are given in Table 12 
90 
for the anti-CL oligo inhibitory effects on the cell lines. 
without oligonucleotide inhibitor, NIH 3T3 cells showed an 
activity of 16.8 pmol/min/102 cells with a standard 
deviation 1.4 in the first 12 hrs. EJ/vHA-ras secreted about 
1.6-fold more CL enzymatic activity than NIH 3T3, whereas 
RASlLeudel cells showed a 4. 8-fold higher CL activity than 
NIH 3T3. CL enzymatic activities in all of the these cell 
lines was not significantly decreased after treatment with 
the sense-uPA oligos from the activity under non-oligo 
treated condition. Treatment with anti-CL decreased the CL 
activity from 33 to 39 % for up to 24 hours. After 24 hours 
the inhibitory effects of the oligos lessened. At 48 hours 
after removal of oligo, the inhibitory effect of the anti-CL 
was not significant. 
7. Investigation of Tumor Metastatic Potentials by Lung 
Colonization Assay 
It has been concluded by several investigators that 
the critical timing for lung colonization in the tail vein 
assay of metastasis is the first 12 hours following the 
injection of tumor cells into mice (Fidler, 1978; Humphries 
et al., 1986; Morikawa et al., 1988). It was observed that 
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the antisense oligonucleotides have an inhibitory effect on 
uPA and CL enzymatic activities, and the inhibitory effects 
of the antisense oligos lasted at least 24 hours after 
removal of oligonucleotide antisense inhibitors from the 
cell culture media. Thus, the duration of inhibition falls 
within the critical time frame for the tail-vein assay of 
metastasis. 
In experiment one, EJ/vHA-ras cells were treated in 
vitro with the oligonucleotides for 24 hours and the oligo 
treated tumor cells (3x105 ) were injected into the tail 
veins of 4 - 6 week athymic (Ncr nu/nu) female mice. The 
mice were sacrificed 14 days later. Lungs were dissected 
from the mice and the number of surface tumors per lung 
counted. The results are shown in Table 13. With the sense 
uPA oligonucleotide treatment (control), injected tumor 
cells produced an average of 130 tumors per lungs. With 
anti-CL oligonucleotide treatment, the injected EJ/vHa-ras 
tumor cells produced an average of 122 tumors per lungs 
which is not significantly different from the control 
treated cells, even though CL activity had been decreased 
35% by the antisense treatment. With anti-uPA treatment (uPA 
activity was lowered 45%), the injected tumor cells produced 
an average of 41 tumors per lung, significantly below the 
control group (p <0.001). 
In experiment two, RAS118udel cells were treated with 
the same oligonucleotides. The treated cells were injected 
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into nude mice and the results are also shown in Table 13. 
The results show that with the sense uPA oligonucleotide 
treatment (for control), injected tumor cells produced an 
average of 94 tumors per lung. With anti-CL oligonucleotide 
treatment (CL enzymatic activities was lowered about 35%), 
the cells produced an average of 26 tumors in lung (p < 0.01 
with respect to control). With anti-uPA treatment (uPA 
activities was lowered by 45%), the injected tumor cells 
produced an average of 81 tumors per lungs, not 
significantly different from the control group. 
Leu The work on RASl del cells were repeated once, and 
the results are displayed on Table 14. With the sense uPA 
oligonucleotide treatment (control), the injected tumor 
cells produced tumors with average 76 per lung. With anti-CL 
Leu 
oligonucleotide treatment, the injected RASl del cells 
produced 29 tumors per lungs (p <.05 by Student' T test; p> 
.05 by nonparametric Wilcoxon rank sum test). With anti-uPA 
oligonucleotide treatment, the injected cells produced 65 
tumors per lung, not significantly different from the 
control group. 
The results from the nude mice experiments suggest 
that either high levels of uPA or CL are induced by 
different ras oncogene transformations, and uPA and CL may 
substitute for each other in the lung colonization 
processes. 
Table 10 uPA secreted Enzymatic Activity of ras-transformed Cell 
Lines Treated with Sense- and Anti-sense Oligonucleotides 
NIH/3T3 
Time after no oligo sense-uPA anti-sense uPA % inhibition 
removal of (100 uM} (100 uM} of uPA 
oligo activity 
-----------------------------------------------------------------------------------
0-12 hr 1. 36a (0.06}b 1.23 (0.06} 0.70 (0.02} 49 
12-24 hr 1.2 (0.1) 1.13 (0.06} 0.61 (0.03} 47 
24-36 hr 0.80 (0.06} 0.75 (0.06} 0.43 (0.03} 44 
36-48 hr 0.65 (0.04} 0.66 (0.06} 0.34 (0.04) 46 
EJ/vHA-ras 
Time after no oligo sense-uPA anti-sense uPA % inhibition 
removal of (100 uM} (100 uM} of uPA 
oligo activity 
----------------------------------------------------------------------------------------
0-12 hr 4.3 (0.2} 4.4 ( 0. 2} 2.3 (0.2} 47 
12-24 hr 3.6 (0.2} 3.3 (0.2} 1.9 (0.2} 45 
24-36 hr 3.1 (0.2} 3.0 ( 0 .1) 1. 7 (0.2} 45 
36-48 hr 2.6 ( 0 .1) 2.3 (0.1} 1.4 (0.2} 44 
-----------------------------------------------------------------------------------""\() 
w 
Time after 
removal of 
oligo 
0-12 hr 
12-24 hr 
24-36 hr 
36-48 hr 
no oligo 
1.1 (0.1) 
0.85 (0.02) 
0.72 (0.02) 
0.63 (0.02) 
Table 10. (continued) 
RASlLeudel 
sense-uPA 
(100 uM) 
1.2 ( 0 .1) 
0.87 (0.01) 
0.71 (0.01) 
0.63 (0.01) 
anti-sense uPA 
(100 uM) 
0.61 (0.02) 
0.55 (0.03) 
0.38 (0.03) 
0.34 (0.02) 
% inhibition 
of uPA 
activity 
45 
44 
47 
45 
------------------------------------------------------------------------------------a 
uPA enzymatic activities determined by chromogenic substrate S-2551. were 
bNumbers are the average of 3 separate runs with units of O.D. per 106 cells per hour. 
The number in bracket is standard deviation. 
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Ta~le 11 CL Enzymatic Activity of ras-transformed Cell Linesa 
Medium Cells-ass. Total Cells-ass. 
/Medium 
-----------------------------------------------------------
NIH/3T3 18.6 3.4 22.0 0.18 
19.5 4.3 23.8 0.22 
20.1 5.2 25.3 0.25 
EJ/vHa-ras 28.6 3.1 31. 7 0.11 
30.8 4.7 35.5 0.15 
31.5 3.8 36.3 0.12 
RAS119udel 77.4 14.1 91.5 0.18 
80.1 15.7 95.8 0.20 
81.8 15.4 97.2 0.19 
aCL enzymatic activities were determined by substrate N-
carbobenzoxy-L-Phe-L-Arg-7-aminomethylcoumarin (Z-Phe-Arg-AMC) 
with units of pmol/min/106 cells. 
Time after 
removal of 
oligo 
Table 12 CL Enzymatic Activity of ras-transformed Cell 
Lines Treated with Anti-CL Oligonucleotide 
no oligo 
NIH/3T3 
sense uPA 
(100 uM) 
anti-CL 
(100 uM) 
% inhibition 
of CL 
activity 
----------------------------------------------------------------------------------------
0-12 hr 16. 8 8 (2.4)b 14.9 (2.6) 10.2 ( 1. 4) 39 
12-24 hr 13.1 ( 2. 3) 12.1 (1. 5) 6.6 ( 1. 4) 34 
24-36 hr 9.6 ( 1. 3) 9.4 ( 1. 5) 7.3 ( 1. 2) 23 
36-48 hr 8.2 ( 1. 4) 8.3 ( 1. 3) 6.9 ( 1. 3) 15 
EJ/vHA-ras 
Time after no oligo sense uPA anti-CL ~ 0 inhibition 
removal of (100 uM) (100 uM) of CL 
oligo activity 
-----------------------------------------------------------------------------------------
0-12 hr 26.4 (3.8) 27.2 (3.7) 16.9 ( 3. 6) 36 
12-24 hr 21. 6 (3.3) 21. 0 (3.3) 14.4 (3.4) 33 
24-36 hr 18.2 (2.2) 18.3 (2.2) 14.4 ( 2. 2) 20 
36-48 hr 13.7 (2.5) 12.9 ( 2. 1) 11.8 (2.4) 14 
----------------------------------------------------------------------------------------'° 
O'I 
Time after 
removal of 
oligo 
0-12 hr 
12-24 hr 
24-36 hr 
36-48 hr 
no oligo 
73.4 ( 11.1) 
52.3 ( 11. 0) 
42.0 (9 .1) 
34.2 (5.8) 
Table 12. (continued) 
RASlLeudel 
sense uPA 
{100 UM) 
69.8 (15.4) 
49.1 (12.9) 
42.4 (13.1) 
33.7 (5.3) 
anti-CL 
(100 uM) 
47.6 ( 8. 5) 
34.2 ( 6 .1) 
35.3 (5.4) 
34.3 (6.5) 
%inhibition 
of CL 
activity 
35 
34 
15 
8 
-----------------------------------------------------------------------------------------
a CL enzymatic activities were determined by substrate N-carbobenzoxy-L-Phe-L-Arg-7-
aminomethylcoumarin (Z-Phe-Arg-AMC). Numbers are the average of 3 separate run with units of 
pmol/min/106 cells. 
bThe number in bracket is standard deviation. 
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Table 13. Lung Colonization of Nude Mice by ras-transtormed 
NIH 3T3 cells Selectively Inhibited by Antisense Oligos• 
oligo Number of tumors/Lung Mean ± s.o. 
----- ---------------------
------
EJ/vHa-ras-transtormed NIH 3T3 Cells 
sense-uPA 105, 113, 115, 121, 137 130 ± 20 
139, 143, 166 
anti-CL 69, 85, 102, 104, 117 122 + 45 
137 147, 213 
anti-uPA 27, 29, 32, 42, 45 41 + 14b 
52, 68 
Leu Rasl del-transtormed NIH 3T3 Cells 
sense-uPA 48, 63, 78, 87, 129, 159 94 + 38 
anti-CL 18, 21, 23, 27, 31, 35 26 + 6c 
anti-uPA 38, 47, 56, 78, 86, 94, 170 81 + 44 
aOligo treated tumor cells (3x105 ) were injected into the tail 
veins of 4 - 6 week athymic NCr (nu/nu) female mice, and the 
mice were sacrificed 14 days later. Lungs were disected from 
mice and the number of surface tumors per lung counted. 
bsignificantly different from other groups at p < 0.001 by 
nonparametric Wilcoxon rank sum test. 
0 Significantly different from other groups at P < 0.01 by 
nonparametric Wilcoxon rank sum test. 
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Table 14. Lung Colonization of Nude Mice by RASl Leudel-
Transformed Cells Selectively Inhibited by Antisense Oligosa 
(Experiment 2) 
Oligo Number of tumors/Lung Mean + S.D. 
-----
---------------------
------
sense-uPA 10, 37, 82, 85, 112, 130 76 + 45 
anti-CL 9, 18, 22, 29, 32, 35, 60 29 ± 16b 
anti-uPA 11, 34, 44, 69, 92, 101, 107 65 ± 37 
aoligo treated tumor cells (3x105 ) were injected into the 
tail veins of 4 - 6 week athymic NCr (nu/nu) female mice, 
and the mice were sacrificed 14 days later. Lungs were 
disected from mice and the number of surf ace tumors per lung 
counted. 
bSignificantly different from other groups at p < 0.05 by 
Student' t test. No significantly different from other groups 
by nonparametric Wilcoxon rank sum test. 
8 • phorbol Ester Induction of Proteases and Protease 
Inhibitors in Buman Prostate carcinoma Cell Lines PC3-P 
and PC3-M 
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In addition to work done on the mouse NIH JTJ cell 
lines, phorbol ester response was also studied in two pairs 
of related human cell lines of different metastatic 
potential. The major properties of these cell lines have 
been described in the Methods Section. 
The PCJ-M (metastatic) cell line was isolated from 
the PCJ-P {parental) and shows a significantly greater 
ability in both spontaneous metastasis and lung colonization 
than the PCJ-P cells (see Table 2) (Kozlowski et al., 1984). 
Figure 9 and 10 show that phorbol ester induces both the uPA 
mRNA and PAI-2 mRNA levels in PCJ-P and PCJ-M cells. The 
mRNA induction follows a time course in which mRNA levels 
increase between 4 and 16 hours, and then decrease by 32 
hours to basal levels. At all time points, uPA and PAI-2 
mRNA levels were compared to that of glyceraldehyde 
phosphate dehydrogenase {GAPD) mRNA which is not stimulated 
by PMA in these cell lines and therefore serves as a 
control. In contrast to the results with ras-transformed 
NIH/3T3 cells, in PCJ cells, the increased ability of the M 
lines to metastasize may correlate most closely with a 
decreased induction of PAI-2 mRNA levels when compared with 
the P lines (parental, low metastatic potential) rather than 
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with an increase in uPA mRNA levels in the M lines. 
stimulation of uPA mRNA in PC3-M cells was only 1.2-fold 
over that of the PMA stimulation of uPA mRNA levels in PC3-P 
cells. However, on PMA induction, the PAI-2 mRNA reached 
levels 6-fold higher in PC3-P (low metastatic) than in PC3-M 
cells (highly metastatic). GADP was not significantly 
induced at the identical conditions. Densitometer traces 
normalized to the GADP mRNA controls and averaged over 3 
independent experiments are shown in Table 15. There is no 
PAI-2 detected in either PC3 - P or PC3-M prior to 
stimulation. PAI-2 mRNA was induced by 2 hours in both PC3-P 
and PC3-M lines, and reached peaks of 3.32 densitometeric 
units (S.D.± 0.8) in PC3-P cells and 0.56 densitometeric 
units (S.D.± 0.07) in PC3-M cells, respectively by 8 hours. 
No apparent inductions with PMA were observed in the GAPD 
mRNA. 
To verify the results for PAI-2 from these slot blot 
analyses, a Northern blot analysis was carried out to study 
the PAI-2 mRNA levels from PC3-P and M cell lines. The 
result is displayed in Figure 11. Without PMA stimulation, 
no PAI-2 was detected in either cell line (lanes 1 and 3). 
Under PMA stimulation (20 nM) for 8 hours, PAI-2 could be 
detected in both cell lines, the P line (lane 4) showed 
significantly higher PAI-2 level than the M lines (lane 2). 
PMA induction of mRNA levels can take place through 
either induction of new protein(s) (transcription factor 
Fiqure 9. Slot Blot Analysis of Human uPA and PAI-2 mRNA 
Levels in PC3-P Cells with PMA Treatment. 
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The PC3-P cells were treated with PMA (20 nM) for 
the designated times and total RNAs were extracted. The RNAs 
were immobilized on a Zeta-probe filter, hybridized with the 
32p-labeled human uPA, PAI-2 and GAPD cDNA probes, and 
exposed to X-ray film. 
("") 
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-
piqure 10. Slot Blot Analysis Of Human UPA and PAI-2 mRNA 
Levels in PC3-M Cells with PMA Treatment. 
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The PC3-M cells were treated with PMA (20 nM) for 
the designated times and total RNAs were extracted. The RNAs 
were immobilized on a Zeta-probe filter, hybridized with the 
32p-labeled human uPA, PAI-2 and GAPD cDNA probes, and 
exposed to X-ray film. 
HOURS (PMA TREATED) 0 2 4 8 16 32 
-
PAl-2 
-
uPA 
GAPD 
PC3-M CELLS 
Table 15. Levels of Human uPA and PAI-2 mRNA 
in PC3-P and PC3-M with PMAa 
PC3-P 
Hours PMA Treated 0 2 4 8 16 32 
uPA/GADP b 0.55 (.12) 1.63(.22) 2.34(.4) 1.82(.32) 1.28(.24) 0.52(.14) 
PAI-2/GADP 
Hours PMA Treated 
b N.O. 
0 
uPA/GADP 0.92(.21) 
PAI-2/GADP N.O. 
0.61(.17) 1.27(.31) 3.32(.76) 1.21(.28) 
2 
1.12(.20) 
0.22(.04) 
PC3-M 
4 8 16 
1.61(.35) 2.41(.72) 2.91(.55) 
0.32(.08) 0.56(.07) 0.28(.03) 
N.O. 
32 
0.85(.19) 
N.O. 
8
mRNAs of the cell lines were determined by slot blots analysis of total 
RNA (4 ug/per slot). Following autoradiography, the intensity of the each slot signal 
was quantified by densitometry. The results were normalized to GADP, which was 
hybridized and densitometrized with the same filter. The numbers are the average 
densitometeric value of 3 separate runs and standard deviation is in bracket. 
b Not observable. ....... 0 
O'I 
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Fiqure 11. Northern Blot Analysis of Human PAI-2 and TIMP 
JDRNA Levels from PC3-P and PC3-M Cells with PMA Treatment. 
Total RNAs were extracted from human prostate 
carcinoma PC3-P and PC3-M cell lines with and without PMA 
(20 nM} treatment. The RNAs were separated by 
electrophoresis through a 1% agarose gel. The RNAs were 
transferred onto a Zeta-probe filter, hybridized with 32P-
labeled human PAI-2 and TIMP inserts. The resulting filter 
was exposed to X-ray film. 
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Fiqure 12. Northern Blot Analysis of Human UPA mRNA Levels 
in PC3-P and M Cell Lines with PMA as well as Cycloheximide 
Treatment. 
Total RNAs were extracted from human prostate 
carcinoma PC3-P and PC3-M cell lines after incubation with 
PMA (20 nM) and/or cycloheximide. Lanes 1 and 5: without 
treatment of PMA and cycloheximide (CHX); lanes 2 and 6: 
treatment with PMA for 16 hours; lanes 3 and 7: treatment 
with PMA (20 nM) and CHX (10 mg/ml) for 16 hours; lanes 4 
and 8: treatment with CHX (10 mg/ml) for 16 hours. The RNAs 
were separated by electrophoresis through a 1% agarose gel. 
The RNAs were transferred onto a Zeta-probe filter, 
hybridized with the 32P-labeled human plasmid uPA insert, 
and exposed to X-ray film. 
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activators) or by a direct stimulation of mRNA synthesis 
through activation of factors that do not require new 
protein synthesis. To explore these different alternatives, 
cycloheximide (10 mg/ml), a protein synthesis inhibitor, was 
added to the cell culture medium for 16 hours. Its effect on 
PMA induction was followed by a Northern blot analysis of 
uPA mRNA, shown in Figure 12. Lanes 1 and 5 contain mRNAs 
isolated from PC3-P and PC3-M cells respectively without 
prior PMA and represent basal levels of uPA mRNA. PMA 
induced uPA mRNA expression in both cell lines (lane 2 and 
6), and cycloheximide added to the cell culture medium 
together with PMA (lanes 3 and 7) enhanced uPA mRNA still 
further in both cell lines. Cycloheximide (lanes 4 and 8) 
alone had no inductive effect. 
9. Phorbol Ester Induction of Protease Inhibitor in Human 
Melanoma Cell Lines A375-P and A375-SM 
The A375-P is a human melanoma cell line with low 
metastatic potential. A375-SM was isolated from the A375-P 
and it shows a substantially greater ability to metastasize 
as measured by a lung colonization assay (see Table 2). 
These cell lines were treated with PMA as described above 
for PC3-P and PC3-M cells. Figure 13 is the Northern blot 
analysis of PAI-2 with and without PMA treatment. PAI-2 mRNA 
could not be detected in either A375-P and A375-SM cell 
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lines two hours after treatment PMA (20 nM), but then 
increased to high levels in A375-P between 8 and 16 hours 
(Figure 15). In contrast, PAI-2 mRNA was only barely 
detectable after 16 hr PMA treatment in A375-SM cells under 
identical conditions (Figure 13). The values from the 
densitometer traces normalized to the GADP mRNA controls are 
displayed in Table 16. The amount of PAI-2 produced by A375-
P was 0.82 densitometer units at 8 to 16 hours, whereas PAI-
2 levels in A375-SM only 0.12 and 0.05 densitometer units at 
the same time points, respectively. Maximum levels of PAI-2 
mRNA were 16-fold higher in the A375-P cells (low 
metastatic) than in the A375-SM cells (highly metastatic). 
In order to follow PMA induction at the protein 
level, a Western blot analysis of human PAI-2 in the two 
human melanoma cells A375-P and SM was carried out. Proteins 
were collected from the cell culture media. Cells were lysed 
and homogenized and the protein concentration of each sample 
determined with the BCA assay (Pierce Chemical Company, 
Rockford, Ill.). Ten mg of protein were loaded into each 
slot of SDS-PAGE gel and electrophoresed. The protein then 
were transferred to a nitrocellulose filter (Bio-Rad) and 
PAI-2 was detected with polyclonal antibodies against human 
PAI-2 (American Diagnostica Inc., New York, NY). The details 
of the assay are discussed in the Methods Section. The 
results are displayed in Figure 14. No PAI-2 was detected in 
either A375-P or A375-SM cell lines prior to PMA treatment. 
Figure 13. Northern Blot Analysis of Human PAI-2 and TIMP 
mRNA in A375-P and A375-SM Cells with PMA Treatment. 
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Total RNAs were extracted from human melanoma cells 
A375-P and SM cells with and without PMA (20 nM) treatment. 
The RNAs were separated by electrophoresis through a 1% 
agarose gel. The RNAs were transferred to a Zeta-probe 
filter and hybridized with the 32P-labeled human PAI-2 and 
TIMP plasmid inserts. The resulting filter was exposed to X-
ray film. 
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Table 16. Levels of PAI-2 mRNA in A375-P and SM Cells 
Hours PMA Treated 
A375-P 
A375-SM 
with PMA Treatment Normalized to GAPDa 
0 
b N.O. 
N.O. 
2 
N.O. 
N.O. 
4 8 
0.12 0.82 
N.O. N.O. 
16 
0.82 
0.12 
32 
0.49 
0.05 
amRNAs of the cell lines were determined by Northern blots analysis of total 
RNA (20 ug/well). Following autoradiography, the intensity of the signals was 
quantified by densitometry. The results were the densitometeric value of PAI-2 
normalized to the densitometeric value of GADP, which was hybridized with the same 
filter. 
bNot observable. 
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With PMA (20 nM) incubation for 24 hours, both cell lines 
produced detectable PAI-2 with the P line giving a higher 
amount than the SM line. Two bands are shown in the Figure 
14, a low Mr band of about 48 kD, and a high Mr band of 96 
kD. The 48 kD band is ostensibly PAI-2 protein (Kruithof et 
al., 1986). The nature of 96 kD band is not clear. The high 
molecular weight band, most likely, is a complex formed 
between PAI-2 and uPA. A similar finding was also reported 
from other laboratories (Nelson et al., 1986). 
10. Induction of PAI-2 in Human Prostate Carcinoma Cell 
Lines PC3-P and PC3-M with conditioned Media 
The surprising observation that PMA induction of PAI-
2 may more closely correlate with metastatic potential than 
the uPA protease activity suggests that gene expressions of 
both protease and protease inhibitors might be altered by 
growth factors in vivo. As PMA is a compound which does not 
exist in the living animal, conditioned media containing 
putative growth factors was collected from mouse organs 
explants for 24 hours. The details of media collection are 
discussed in the Methods Section. The conditioned medium was 
used to replace PMA in treating PC3-P and PC3-M cell lines. 
PAI-2 gene expression was measured by a Northern blot 
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Figure 14. Western Blot Analysis of Human PAI-2 Protein in 
pc3-P and M Cells with PMA Treatment 
Ten mg of the proteins sample was loaded into each 
slot of a SDS-PAGE gel, and separated by electrophoresis. 
The proteins were transferred to a nitrocellulose filter. 
PAI-2 polyclonal antibody was used as a primary antibody, 
followed by goat anti-mouse antibody {Sigma Chem. Co.) 
conjugated with alkaline phosphatase. 
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analysis. The result is displayed in Figure 15. No PAI-2 
mRNA was detected in either PC3-P and M cells cultured in 
normal medium (lanes 1 and 5) and in conditioned medium from 
kidney (lanes 3 and 7), and spleen conditioned medium (lanes 
4, 8). However, incubation of the cells with conditioned 
medium from the lung organ culture showed a stimulating 
effect. Both PC3-P and M produced PAI-2 mRNAs, with higher 
induction in the P cells than the M cells (lanes 2 and 6). 
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Figure 15. Northern Blot Analysis of Human PAI-2 mRNA from 
PC3-P and M Cells Treated with the conditioned Medium 
Total RNAs were extracted from human prostate 
carcinoma PC3-P and M cell lines after incubation with 
different conditioned media. Lanes 1 and 5: control with 
normal medium; lanes 2 and 6: treatment with lung 
conditioned medium for 16 hours; lanes 3 and 7: treatment 
with kidney conditioned medium for 16 hours; lanes 4 and 8: 
treatment with spleen conditioned medium for 16 hours. The 
RNAs were separated by electrophoresis through a 1% agarose 
gel. The RNAs were transferred onto a Zeta-probe filter, 
hybridized with the 32P-labeled human PAI-2 insert, and 
exposed to X-ray film. 
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Chapter V 
DISCUSSION 
Constitutively High Expression of Different Proteases 
in Cell Lines with Different ras-transformations 
EJ/vHa-ras cells were produced by Bradley et al., 
(1986) by transforming NIH 3T3 cells with a chimeric ras 
construct containing two activating mutations, at codons 12 
and 59 (Gibbs, et al., 1984). RASlLeudel cells were similarly 
developed by Bradley et al. (1986) by transfecting NIH 3T3 
cells by an homologous yeast RASl sequence activated by the 
substitution of a Leu at position 68 (analogous to position 
61 in the mammalian Ha-ras sequence). Both cell lines were 
shown to have very high metastatic potentials in a nude 
mouse lung colonization assay (Bradley et al., 1986). In my 
study I show that the EJ/vHa-ras cells express a similar 
constitutive level of CL mRNA as untransformed NIH 3T3 
cells, but a 5.4-fold higher constitutive level of the mRNA 
for the protease uPA with compared with NIH 3T3 cells (Table 
Leu 5). In contrast, RASl del cells show low levels of 
constitutive uPA mRNA but a 4.4-fold higher concentration of 
the mRNA for the protease CL when compared with NIH 3T3 
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cells (Table 5). 
Chromogenic substrate assays were used to study the 
enzymatic activities of uPA and CL in these cells. The 
substrate N-carbobenzoxy-L-Phe-L-Arg-7-aminomethylcoumarin 
(Z-Phe-Arg-AMC) was used to assay for cathepsin L-like 
activity (Mason, 1986; Baricos et al., 1988). The uPA 
enzymatic activity was determined with the chromogenic 
substrate S-2551, which measures the activity of plasmin 
generated following uPA treatment of plasminogen. The CL-
Leu like activity of the RASl del cells was found to be 3.8-
fold higher than in its non-transformed parental NIH 3T3 
cells, whereas CL activity of the EJ/vHa-ras cells was only 
1.6-fold higher than in the NIH 3T3 cells. The highest uPA 
enzymatic activity was found in EJ/vHa-ras cells, and was 
3.2-fold higher than in NIH 3T3 cells. The uPA enzymatic 
Leu 
activity of RASl del cells was only 80% of the NIH 3T3 cell 
line. The enzymatic activities of the ras-transformed cell 
lines are, thus, proportional to the different mRNA levels 
found in these cell lines. The results showed that higher 
constitutive levels of either uPA and CL are associated with 
cells transformed with the EJ/vHa-ras or RASlLeudel cells, 
respectively. 
The concentrations of CB mRNA has also been measured 
with the slot blot assay. The result is not as dramatically 
different as CL and uPA among the different ras transformed 
cell lines. The highly metastatic EJ/vHA-~ only had a 1.9-
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fold increase in CB mRNA over NIH 3T3 cells. The highly 
metastatic RASlLeudel cell had a 1.5-fold increase in CB mRNA 
above NIH 3T3 cells. Thus, the contribution of CB may not be 
a major factor affecting the tumor metastatic potentials of 
these cell lines. 
Different Responses of ras-transf ormed Cell Lines to 
PMA 
The gene expressions of the proteases are affected in 
vitro by many hormones, growth factors, and phorbol ester 
{Sloane et al., 1987; Markus, 1988). There has been very 
little research comparing the differential expressions of 
proteases in cell lines derived from same parental cell line 
and transformed with different oncogenes. It is a part of 
the hypothesis of this project that the proteolytic 
activities of tumor cells may be modified in vivo by signal 
factors, and different oncogene transformation may lead to 
different responses to the signal factors. 
As it is currently impossible to study how the 
protease activities are actually regulated in vivo by signal 
factors, phorbol-12-myristate-13-acetate (PMA), a 
diacylglycerol (DAG) analog, was used to activate the 
protein kinase C {PKC) in the inositol phosphate signal 
pathway (see Literature Section). The PKC pathway is one of 
the major signal transduction pathways used by exogenous 
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signal factors and the pathway is presumed to be utilized by 
in vivo signal mechanisms. 
Subconfluent cultures of cells were treated with 20 
nM PMA and the total RNA was isolated by standard techniques 
at o, 2, 4, 8, 16 and 32 hours. The variations of protease 
mRNA levels at these time points were determined by a slot 
blot technique. On PMA treatment, increases in uPA mRNA 
levels occur in the EJ/vHa-ras and EJ-ras transformed cells 
as well as untransformed NIH 3T3 cells. In contrast, there 
was no induction of uPA mRNA in cells transformed by the 
Leu Leu yeast RASl del sequence or the yeast HYB c sequence. Thus 
RASlLeudel transformations appear to suppress the normal PMA 
induction of uPA mRNA, which is stimulated in EJ-ras and 
EJ/vHa-ras transformed cells and untransformed NIH 3T3 
cells. 
Recently, Givol cloned (Givol, et al., 1992) three 
ras genes with different mutations at codon 12 into the same 
vector and used these ras oncogenes to transform chick 
embryo fibroblasts. When the clones were introduced into 
chick embryo, three types of organ specificity of the 
metastatic tumors were observed, which were dependent on the 
amino acid substitution at codon 12. The outcome of this 
project correlates with this organ-specific metastasis 
experiment. Every organ has its specific signal factors 
profile, which may cause a diverse protease and protease 
inhibitor expression among the cells transformed with 
different ras oncogenes. 
Both constitutively High Protease Levels and PMA 
Response Are Mainly Due to Changes in Transcription 
Rate 
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In order to determine the mechanism of PMA 
inducibility of uPA, CL and CB mRNA, a nuclear transcription 
(run-on) assay was carried out. Without PMA treatment, the 
CL transcription rate in RAS11eu cells is 6-fold higher than 
NIH 3T3 cells while the rate in EJ/vHa-ras cells is 2.5-fold 
higher than NIH 3T3 cells. The uPA transcription rate of 
EJ/vHa-ras cells is 7-fold higher than NIH 3T3 cells (Table 
5). The results on the relative constitutive level of uPA is 
also confirmed by Dr. Silberman in this lab with CAT assays 
utilizing part of the 5' promoter region of the uPA gene as 
an enhancer in a CAT vector with the a heterologous SV40 
promoter. In these experiments, CAT activity was 7-fold 
higher in EJ/vHa-ras cells than NIH 3T3 cells, while CAT 
activity in RASlLeu transformed cells was equal to that in 
NIH 3T3 cells (S. Silberman and R. M. Schultz, personal 
communication). The difference in transcription rates of CL 
and uPA in these cell lines are consistent with difference 
observed in these cell lines in their mRNA levels and in 
their levels of expressed enzymatic activities. 
With PMA treatment for 2 hours, uPA transcription 
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rate increased 4-fold in the NIH 3T3 cells, 3.6-fold in the 
Leu EJ/vHa-ras cells and only 10% in RASl cells. In contrast, 
a 2 fold PMA stimulation of CL transcription is observed in 
RASl Leu cells. No stimulation by PMA of CL transcription is 
observed in the EJ/vHa-ras or NIH 3T3 cell lines. 
The results are summarized in the hypothetical scheme 
of Figure 16 which displays independent pathways for 
activated yeast RASl, activated mammalian-like ras, and the 
PKC signal transduction pathway through non-activated 
cellular p2lr~. PKC may control the activation of p2lr~ by 
its down-regulation of GAP (Downward et al., 1990). c-Fos 
and c-Jun are transcription factors activated by the 
PKC/p21c-~ signal transduction pathway {Cai, et al., 1990). 
The scheme then depicts the results of this work: (i) the 
high constitutive expression of the uPA gene induced by 
mammalian/viral EJ/vHa-ras transformation and the PMA 
inducibility of uPA in mammalian ras-transformed (as well as 
untransformed) NIH 3T3 cells, (ii) the repression of PMA 
induction of uPA transcription in cells transformed by 
Leu Leu 
activated RASl sequences {HYB c and RASl del transformed 
cells), (iii) the high constitutive expressions and PMA 
inducibility of CL and CB genes in HYB CLeu and RASlLeudel 
transformed cells, and (iv) the lack of a PMA induction of 
the CL gene in mammalian-like ras and untransformed NIH 3T3 
cells. 
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Putative Mechanisms for Differential Responses to 
PMA in the ras-transf ormed Cell Lines 
The dissimilar patterns of protease expressions inf er 
the existence of at least two discrete signal transduction 
pathways for Ras oncoproteins leading to alternate 
phenotypes for the transformed state. The observation of 
multiple pathways may be in agreement with the recent report 
that more than one type of GAP protein can bind to the 
effector site in Ras, and both GAPs are present in equal 
amounts in NIH 3T3 cells (Bollag and McCormick, 1991; Vogel 
et al., 1988). The increases observed in one or the other 
pattern for protease expression, depending on the mutated 
form of the ras oncogene, further shows the presence of 
alternative compensating protease pathways which may exist 
for the degradation of extracellular matrix during 
metastasis even in transformed cells obtained from the same 
parental cell line. 
In humans, there are at least two genes encoding 
proteins which stimulate the GTPase activity (GAP). One of 
molecular mass 120,000 daltons is referred to as pl20GAP' and 
GAP GAP . the other NFl (p280 ) is encoded by the neurof ibromatosis 
GAP GAP , type-1 gene. p120 and NFl proteins bind to the same 
effector site in Ras, and it is the heterodimer of GAP-RASGTP 
that is believed to transmit the downstream effector signal 
from Ras (Martin et al., 1990; Bollag and McCormick, 1990). 
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EJ/vHa-ras has an activating mutation at codon 12 while 
RASlLeudel has an activating mutation at codon 68 (equivalent 
GAP to codon 61 in Ha-ras) . The affinity of the p120 has been 
showed to increase significantly, when these mutations are 
GAP present. Accordingly, the affinity of pl20 may be better 
to RASlLeudel with mutated codon at 68 as compared to its 
binding affinity to mutated codon 12 in the EJ/vHa-ras. As 
GAP GAP , p120 and p280 have been shown to be present in 
approximately equal concentrations in NIH 3T3 cells (Martin, 
et al., 1990, Bollag and McCormick, 1990), it may be that 
changes in amino acid codon from 12 (in EJ/vHa-ras) to codon 
68 (in RASlLeudel) changes the relative affinities and thus 
the type of the GAP effector associated with the respective 
activated Ras protein. This putative change in the GAP 
effector could cause the switching of the signal from one 
biochemical pathway to the other. It is possible that the 
NFlGAP_Ras and the p120GAP_Ras complexes activate different 
pathways for the transformation and generation of the 
metastatic phenotype. 
Figure 16. Hypothetical Pathways for Normal Ras and 
Activated Mammalian and Yeast Ras Regulation of Pro-
metastatic uPA, CL and CB Protease Genes. 
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Suppression of uPA induction by the PKC/p21°-~ 
pathway in yeast RASl-transformed cells shown by negative 
symbol. Dotted line indicates the inducibility of CL and CB 
genes by the PKC/p21°-~ pathway only in yeast RASl 
transformed cells. 
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Anti-sense Oliqonucleotides can Partially Inhibit 
uPA and CL Enzymatic Activities in A Transient 
Manner 
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Advances in molecular biology and synthetic chemistry 
over the past two decades have stimulated research into the 
use of antisense oligonucleotides as potential therapeutic 
and research agents (Rothenberg et al., 1989). Although some 
limitations, such as short half-lives in vivo and 
cytotoxicity, prevent the use of unmodified oligonucleotide 
as therapeutic agents, there are still reports of successful 
applications to influence the expression of a given gene of 
interest. For example, Zamecnik et al. (1986) and Goodchild 
et al. (1988) demonstrated inhibition of HIV replication 
upon addition of antisense oligonucloetides targeted against 
viral mRNA. studies by Wickstrom et al. (1988) and Holt et 
al. (1988) demonstrated repression of HL60 cell 
proliferation and c-myc expression following addition of 
antisense oligonucleotide directed against human c-myc mRNA. 
Oligonucleotides complementary to c-myb-encoded mRNA was 
shown to inhibit normal human hematopoiesis in vitro (Geirtz 
and Calabretta, 1988) and proliferation of human myeloid 
leukemia cell lines (Anfossi et al., 1989). An antisense 
oligonucleotide to basic fibroblast growth factor repressed 
proliferation of human malignant melanomas (Dorothea et al., 
1989). No general tenet for prediction of the effectiveness 
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of a given oligonucleotide has been suggested. The process 
seems to be system- and sequence-specific. In this work, 
three 21-mer deoxyoligonucleotides was prepared: sense-uPA 
(5'-ATGAAAGTCTGGCTGGCGAGC-3'), anti-uPA (5'-
GCTCGCCAGCCAGACTTTCAT-3'), and anti-CL (5'-
CAAAAGGAGTAAAAGATTCAT-3'). Anti-uPA and anti-CL were 
prepared in an antisense direction (3' -> 5') of the first 
21 nucleotides from the 5' start of translation in the mRNAs 
for murine uPA and CL, respectively. NIH 3T3 cells, and EJ-
vHa-ras- and RAS110udel-transformed cells were incubated with 
100 uM of these oligos in the media containing 10% FBS for 
24 hours. The oligo containing culture media was removed and 
replaced with the oligo-free, serum-free medium. The CL and 
uPA activities produced by the cells were tested in the 
serum-free medium. The assay became impossible after 48 
hour, as majority of the cells became detached from the 
flasks in the cell culture. Enzymatic activities of uPA and 
cathepsin L were determined by chromogenic or f luorogenic 
substrates as described in methods. 
In contrast to our expectations, the non-chemically 
modified oligonucleotides significantly inhibited the 
respective gene expressions, even if just in a transient 
manner. Accordingly the synthesis of s-oligos was not 
Leu 
required. In both EJ/vHa-~ and RASl del-transformed cell 
lines, anti-sense uPA selectively inhibited 44-49% of uPA 
activities up to 48 hrs; and anti-sense cathepsin L 
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selectively inhibited 33-39% of the CL enzymatic activities 
up to 24 hrs. The different durations of inhibition may be 
related to the different abundance of the uPA and CL mRNA 
inside the cells. 
Lunq Colonization Assay 
To measure the effect of anti-sense oligonucleotides 
one metastatic potential, nude mouse lung colonization 
assays were employed. The ras-transformed cells were treated 
in vitro with the oligonucleotides described above for 24 
hours, the oligo-treated cells were injected into tail veins 
of nude mice , and 2 weeks later the animals were sacrificed 
and the tumor nodules on the lung counted under a dissecting 
microscope. This assay measures tumor cell extravasation 
from the blood stream with invasion of basement membrane and 
extracellular matrix, and then growth into pulmonary tumors. 
If a change in the number of metastatic colonies is 
evidence for the effect of the oligo on the metastatic 
process, it is important that the method for determining the 
number of metastatic colonies be accurate and reproducible. 
As stated by Fidler (1978), and discussed in the references 
therein, most lung tumors in mice appear on the surface and 
can be counted with a dissecting microscope. 
There is some variation in the number of metastases 
between control groups used in different experiments, but 
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they are not statistically different. The variation probably 
results from using cells maintained in culture for different 
lengths of time as well as the use of different batches of 
mice. As a valid control group was utilized with each 
experimental group, the dissimilarity in the number of lung 
colonies between different control groups carried out on 
different days with different lots of mice, should not 
affect the conclusion of the project. 
Anti-sense Oligonucleotides can Selectively Decrease 
Tumor Metastatic Potential in Particular Cell Lines. 
As noted above, uPA and CL was shown to be more 
Leu highly expressed in EJ/vHa-ras and RASl del transformed 
cells, respectively. Expressed enzymatic activities of uPA 
and cathepsin L were significantly inhibited by the 0-
oligonucleotide in a transient manner, as measured with 
fluorogenic substrates. In both EJ/vHa-ras cell line and 
RAS11eudel cell line, anti-sense oligo inhibited at least 34% 
of the enzymatic activities up to 24 hrs. The time course of 
the initial arrest and invasion by tumor cells of an organ 
in vivo, after tail vein injection, has been evaluated by 
radiolabeling of a tumor cells with 1125 2-iodo-deoxy-uridine 
(Fidler, 1978). The result showed the critical time in lung 
colonization for cell adhesion and invasion is the first 12 
to 24 hours after tail vein injection of the cells. 
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Both uPA and CL have been implicated as enzymes 
capable of much extracellular tissue destruction, including 
the degradation of extracellular basement membrane. The 
production of high levels of uPA and CL has been shown to 
correlate with high levels of metastasis. Direct evidence 
has shown that uPA plays a role in B16 melanoma metastasis 
in C57BL mice (Yu and Schultz, 1990). 
In this project, anti-sense oligo compounds have been 
shown to be specific inhibitors of the proteolytic enzymes 
cathepsin L and uPA in vitro. If uPA or CL is crucial to the 
metastatic process in vivo in these cell lines, then 
inhibition of the protease activities may lead to a 
reduction of metastasis in a lung colonization assay. 
Treatment of the cells with the anti-sense oligo prior to 
injection of cells into nude mice would be expected to lower 
the protease activities in the treated cells for at least 24 
hours. Accordingly, the cells were injected immediately 
after ceasing treatment with the anti-sense oligo. The 
results were expected to give a clear picture as to the 
importance of the particular protease in metastasis in vivo. 
The nude mice experiments tests the hypothesis of the 
selective involvement of proteases in different ~­
transformed cells lines. 
Experiment 1 utilized EJ/vHa-ras cells. The result 
{Table 13) shows that the sense-uPA treated cells (control 
oligo) produced an average of 130 tumors per lung. The anti-
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CL treated cells gave an average of 122 tumors per lung, 
which is not statically different from the control group. 
The anti-sense uPA-treated cells produced an average of 41 
tumors per lung, significantly below the control group (P < 
0. 001) . 
Leu Experiment 2 used RASl del cells. The results showed 
that the sense uPA treated cells (control oligo) produced an 
average of 94 tumors per lung. The anti-uPA treated cells 
produced an average of 81 tumors per lung, not significantly 
different from the control group. The anti-CL treated cells 
produced an average of 26 tumors in lungs which was 
significantly lower than the control (p < 0.01). 
The latter work was repeated once more, the number of 
tumors per lung was more variable than in the preceding 
experiment (Table 14), but the anti-CL treated cells still 
caused significantly fewer lungs colonies when compared with 
the sense-uPA treated cells (P < 0.05 ). 
Tumor metastatic potential does not appear to be 
directly proportional to changes in the protease activity of 
tumor cells. For example, anti-CL inhibits CL enzymatic 
activity by 35% in RAS110udel cells, in which the total tumor 
lung colonizations is reduced 70% with respect to the 
controls group. 
As CL inhibition in EJ/vHa-ras cells and uPA 
inhibition in RAS110udel cells had no effect on lung 
colonization ability, there may be a threshold amount of uPA 
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or CL required for promotion of metastasis. CL concentration 
I 11 d t t , , Leud l in EJ vHa-ras ce s an uPA concen ra ion in RASl e 
cells, respectively, may be too low to affect lung 
colonization ability one way or another. Therefore, 
inhibition of their already low respective activities had no 
affect. On reaching a threshold level, metastatic ability 
then becomes dependent on their relative amounts. 
The results of the lung colonization assay with anti-
sense inhibitors clearly show that metastasis can be 
achieved with aid of alternative proteases. uPA and CL 
proteases were separately induced by different ras oncogene 
transformations. uPA and CL may compensate for one another 
in tumor metastasis. 
Direct Evidence for Involvement of CL in Tumor 
Metastasis 
Although an increase of CL has been reported to be 
correlated with tumor metastatic potentials (Gottesman, 
1988), this correlative evidence by its nature is an 
indirect type of evidence. The specific inhibition of CL 
synthesis by anti-CL and corresponding decrease in lung 
colonization observed in this project is the first direct 
evidence for a role of CL in tumor metastasis. 
A problem in assigning a role to CL in tumor 
metastasis is that CL is an acidic protease, its optimal pH 
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for activity is 4. At neutral pH, which is the expected pH 
of the extracellular space in the tumor invasion process, CL 
enzymatic activities should be low. In addition, prior 
evidence indicated CL was unstable at neutral pH, and thus 
its activity will be predicted to last only a short time 
(Gottesman, 1987). These properties of CL implied that CL 
may not be a crucial enzyme in metastasis. 
The doubts can be addressed in several ways. First, 
CL is secreted as a proenzyme, which is stable at neutral 
pH, and hence may be an excellent molecular vehicle for the 
transfer of the protease in a cancer cell to the 
extracellular environment. After secretion, procathepsin L 
must be activated to its functional form. The mechanism of 
activation is unknown. Secondly, even the mature form of 
cathepsin L shows activity at neutral pH, albeit briefly 
(Mason et al., 1987). In addition, CL could act in an acidic 
microenvironment in the region of contact between the cell 
surface and the extracellular matrix or basement membrane. 
Secreted procathepsin L passes through the acidic 
vesicles of the exocytic pathway in cancer cells. It might 
act in this compartment to process, and perhaps activate, 
cell surface receptors and secreted growth factors. 
Increased amounts of cathepsin L in various intracellular 
compartments, including the lysosomes of cancer cells, could 
facilitate protein turnover during the growth of these cells 
(Laumas et al., 1989). Cathepsin L could also be essential 
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for the activation or inactivation of oncogene or anti-
oncogene products or other intermediates in the process of 
malignant transformation. In addition to a possible direct 
role of cathepsin L in tumor metastasis, cathepsin L might 
interfer with antigen processing with the potential ablation 
of the immune response to tumors {Mouritsen et al., 1991). 
PMA Induces More PAI-2 in Human Tumor Cell Lines with 
Less Metastatic Potential 
The activity of uPA can be regulated through control 
of the amount of protease synthesized, or through the 
production of its inhibitor(s). Some proteinase inhibitors 
such as a2 -macroglobulin, al -proteinase inhibitor, and 
antithrombin III inhibit a wide spectrum of proteases. As 
their molecular weights are large and their activities are 
non-specific in nature, these protease inhibitors are not 
commonly thought to be of importance in precise control of 
proteinase activity in tumor metastasis in vivo {Markus, 
1988). However, there are at least two plasminogen activator 
inhibitors (PAis) that bind PAs specifically, PAI-1 and PAI-
2. The pertinent information on these PAis have been 
reviewed in the Literature Section. 
The PC3-P and PC3-M cell lines are from a human 
prostate carcinoma. The PC3-P {parental) cell line has a 
significantly lower metastatic potential in the nude mice 
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assay (Kozlowski et al., 1984), while the PC3-M cell line is 
a derivative of the P line with a higher metastatic 
potential (see Table 2). 
A375-P & A375-SM cell lines are derived from a human 
melanoma. A375-P cells show a low metastatic potential in 
the nude mice assay, and A375-SM cells show a higher 
metastatic potential than A375-P cells (see Table 2) 
(Kozlowski et al., 1984). 
Initial efforts to correlate uPA levels and tumor 
metastatic potential in the PC3 and A375 cell lines failed 
to detect any meaningful relationships. Attempts have also 
been made to obtain a purposeful relationship between PAI-2 
and tumor metastatic capability. However, no PAI-2 mRNA was 
observed under basal conditions in these cells. However, on 
treatment of these cell lines with PMA, both the PC3 and 
A375 lines show observable increases of the uPA and PAI-2 
mRNAs. In particular the less metastatic P lines make more 
PAI-2 mRNA than the more metastatic M-line. The ability to 
metastasize may thus correlate better with an increased 
induction of PAI-2 mRNA levels in the P lines (parental, low 
metastatic potential) than with an increase in urokinase 
mRNA levels in the M lines (high metastatic potential). Data 
showed that stimulation of uPA mRNA in PC3-M cells was only 
20% (1.2-fold) over that of the PMA stimulation of urokinase 
mRNA levels in PC3-P cells. In both the A375-P and M cell 
lines, no uPA mRNA was observable even with PMA treatment. 
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However, with PMA induction, both cell lines (PC3-P and 
A375-P) with lower metastatic potentials produced much more 
PAI-2 mRNA than those of their partners with high metastatic 
potentials (PC3-M and A375-SM) (6-fold higher in PC3-P, 16-
fold higher in A375-P). In addition, mRNA for a collagenase 
inhibitor, TIMP, was also much more highly induced in the 
A375-P than in the A375-SM cells (3-fold higher in A375-P). 
Attempts were made to assay PAI-1 with a cDNA probe 
for PAI-1 mRNA in these cell lines. No hybridization was 
observed after extensive trials. 
Although there are many prior studies on protease 
inhibitors such as PAI-2 and TIMP, few reports have directly 
connected PAI-2 with metastatic capacity of tumors until 
recently. This work is among the first studies correlating 
the tumor metastatic potentials with the uPA inhibitors 
levels as opposed to uPA itself. The significance of 
difference in the inductions of PAI-2 for tumor metastasis 
is not yet clear, as we have not yet shown that an antisense 
oligonucleotide for PAI-2 can promote metastasis. However, 
induction of PAI-2 in vivo in both cell lines is a likely 
event and may occur through PKC. In addition, our data 
implicates the importance of signal transduction pathways in 
inducing both pro- and anti- metastatic promoting gene 
expressions, and suggests an important role for protease 
inhibitors in determining the metastatic potential of a 
cell. The variations in PAI-2 levels may be more important 
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than variations in urokinase levels in determining the net 
urokinase activity and consequently the metastatic potential 
of the cell lines PC3 and A375. 
Superinduction of uPA by Cycloheximide 
To test whether protein synthesis is required for the 
effect of PMA on the PAI-2 mRNA level, PC3-P and M cells 
were incubated for 24 hr with PMA, cycloheximide (CHX), and 
a combination of the two compounds. Total RNAs were isolated 
from the cells and analyzed by Northern blotting. Inhibition 
of protein synthesis by CHX does not inhibit the induction 
by PMA of uPA mRNA synthesis in these cell lines. Rather the 
combination of PMA and CHX produces a 2.5-fold higher level 
of uPA mRNA than PMA alone. Thus, cycloheximide leads to a 
superinduction of uPA mRNA under PMA stimulation. 
Superinduction of gene expression by incubation of 
cultured cells with CHX as inducer has been described in a 
variety of systems, such as superinduction of tPA mRNA in 
isoproterenol-treated granulosa cells (Oikawa and Hsueh, 
1989), PAI-2 in the human promyelocytic cell line HL-60 
(Antalis and Dickinson, 1992), and the induction of uPA in 
Hela cells (Novak et al., 1991). The exact mechanism(s) 
underlying the superinduction by CHX in cells is unknown. 
There are a few exOplanations for the marked accumulation of 
uPA mRNA in the presence of PMA and CHX on the cells 
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studied. The superinduction is probably not due to a 
stabilization of uPA mRNA by CHX, as CHX alone did not 
result in an increase in levels of uPA mRNA. However, in the 
3 1 end of uPA a consensus AUUA sequence is found (Verde et 
al., 1985), and this sequence has been shown to confer the 
superinduction effect of CHX. The CHX effect might work on 
protein(s) induced by PMA which modulate the increases in 
the mRNA transcription rate normally observed with PMA 
induction, or increase the uPA mRNA degradation rate. In 
absence of the protein synthesis inhibitor, the full effect 
of PMA induction is observed. 
Conditioned Medium Induce More PAI-2 in Human 
Prostate PC3-P Cells Than in PC3-M Cells 
Considerable efforts has been made in this project to 
study the different response of transformed cells to the PKC 
activator PMA. As PMA is a compound isolated from a plant 
and does not exist inside the body of animals, the data 
based on PMA work is only a hypothesis. The idea needs to be 
extrapolated to tumor metastasis in the animal. We do not 
know, however, the identity of the signal factor(s) in vivo. 
To try to find a signal factor(s) in vivo, a dozen purified 
growth factors and hormones that are commercially available 
were utilized as a replacement of PMA in stimulation 
experiments in cell culture. The factors studied were 
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platelet-derived growth factor (PDGF), epidermal growth 
factor (EGF), interleukin 1, interleukin 6, and nerve growth 
factor (NGF). However, all these factors failed to produce 
any stimulation of the proteases and inhibitors in the human 
tumor cell lines PC3-P, PC3-M, A375-P and A375-SM. Finally, 
the conditioned media from nude mice organ cultures were 
collected, and used to culture these cell lines. 
PC3-P and M cells were cultured with conditioned 
media collected from lung, kidney and spleen of female nude 
mice, and the RNA were isolated from these cells after 16 
hr. uPA and PAI-2 cDNA were used as a probe in Northern blot 
analysis of these cell lines. The astonishing result was 
that treating PC3-P and M with the conditioned medium from 
lung organ culture induced PAI-2 production in similar 
pattern to that shown on PMA stimulation. No effect on PAI-2 
mRNA induction was observed with any of the other organ 
conditioned media. uPA mRNA is not significantly altered 
with incubation of the conditioned media. Furthermore, these 
cells only metastasized to the lung in nude mice assays of 
the metastatic potential of these cell lines (Kozlowski et 
al., 1984a, 1984b). The outcome shows there exist 
stimulator(s) in lung, which can modify the protease 
activities in similar fashion as does PMA in these cell 
lines. Also, the effect is apparently on PAI-2 mRNA levels, 
not on the uPA mRNA levels. 
The nature of the stimulator existing in lung 
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conditioned medium is unknown. The effect may be caused by a 
single signal factor, or a combination of growth factor(s) 
(Beutler and Cerami, 1986; Roberts et al., 1985). 
Although similar observation was found with the 
conditioned medium, the strength of the effector in the 
conditioned medium was less than PMA (20 nM). This 
conclusion was obtained from time length of film exposure in 
Northern blot analysis required to achieve a similar density 
of hybridization (data not shown). This may be due to both a 
short half-life and/or the strength of the effector in the 
conditioned media resulting in a less effective stimulation 
than PMA in these experiments. 
General Principle of Proteases Involved in Tumor 
Metastasis 
The increases observed in one or the other pattern 
for protease expression, depending on the mutated form of 
the ras oncogene, further indicates the presence of 
alternative compensating protease pathways which may exist 
for the degradation of extracellular matrix during 
metastasis, even in transformed cells obtained from the same 
parental cell line. The antisense oligo data show that in 
one pathway uPA is an important facilitator of experimental 
metastasis (lung colonization), while in the second pathway 
CL facilitates experimental metastasis. A role for proteases 
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in metastasis has long been suggested, but direct evidence 
for a role of particular proteases has not been clear-cut. 
In part, the confusion is due to the large amount of 
correlative evidence from miscellaneous systems with 
different proteases, which are often contradictory. Direct 
evidence for a role of a particular protease in metastatic 
processes only comes from the few experiments in which 
selective inhibitors of proteases were utilized (Schultz, et 
al., 1988), and from molecular biology experiments in which 
particular protease gene expressions can be selectively 
increased or decreased (Yu and Schultz, 1990). However, an 
additional factor contributing to the confusion is the 
possibility that an enzyme activity required for the 
metastatic process in one tumor cell type may be not 
required in another. This project show a reciprocal 
variation for the importance of CL activity and uPA activity 
in the different ras-transformed NIH 3T3 cells. The data 
supports the hypothesis that different biochemical pathways 
exist that generate different malignant phenotypes, even 
within the same parental cell type that use a different set 
of proteases to achieve metastasis. In addition, this 
project obtained the first direct evidence for the 
importance for CL in metastasis. 
Although the complexity of proteases involved in 
tumor metastasis is now appreciated, the result from this 
project may contribute to some general principle in this 
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field. Firstly, there is unlikely to exist a universal 
protease produced by all cancer cells which can account for 
the invasive and metastatic properties in cancer. Rather, 
different cancers appears to employ different protease(s), 
or combinations of proteases, to achieve the same end. The 
decision as to which protease or proteases a specific tumor 
type will use probably depends on the tissue of origin of 
the cancer and the manner in which transformation is 
achieved. 
Secondly, differences in protease mRNA levels and 
their activity observed in vitro may, or may not, be 
reflective of the actual protease activity expressed by 
those cells in vivo. In vitro studies often fail to show a 
correlation of protease activity with invasiveness in vivo. 
Partial reasons for the bewilderment is that spectrum of 
proteases observed in vitro in a tumor cell may be modified 
in vivo. Possibly, the majority of observations in vitro 
acquired up to now do not represent the true protease 
activities actually involved in in vivo tumor metastasis. 
Thirdly, the oncogenic mechanism causing increases of 
protease activity is unclear. In some cases, increased or 
decreased transcription of the protease gene may occur. In 
other cases, gain or loss of activity of specific inhibitors 
appears to contribute significantly to the activity of the 
protease. 
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As it is currently not possible to study how the 
proteases activities are actually regulated in vivo by 
signal factors, I studied phorbol-12-myristate-13-acetate 
(PMA or TPA) which mimics diacylglycerol (DAG) in activating 
the protein kinase C in the inositol phosphate signal 
pathway. 
To investigate the question related to mechanism of 
transformation, I used a group of mouse cell lines 
transformed by different ras oncogenes that show different 
metastatic potentials in a nude mice assay system. NIH 3T3 
cells are non-transformed mouse fibroblasts without 
tumorigenic properties. The EJ-ras and EJ/vHa-ras cell lines 
are NIH cells transformed by activated mammalian ras 
Leu Leu , 
oncogenes. Hyb c and RASl del cell lines are NIH 3T3 
cells transformed by yeast ras oncogene constructs. 
By Northern and slot blots analysis of the RNAs for 
mouse cathepsin B, L and urokinase, I studied mRNAs 
expressed both constitutively and with phorbol ester 
stimulation. These data show: 1) urokinase is at a 
significantly higher constitutive level in the highly 
metastatic EJ/vHa-ras line, but not in the highly metastatic 
RASlLeudel cell line. 2) PMA stimulates urokinase mRNA in 
untransformed NIH 3T3 and in the mammalian-ras transformed 
cells, but did not stimulate urokinase mRNA in yeast 
Leu RASl del transformed cells. 3) CL mRNA is significantly 
higher in highly metastatic RASlLeudel cell lines as compared 
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with other cell lines. 4) PMA strongly induce CL mRNA in 
Leu Leu • yeast ras transformed HYB c and RASl del lines but PMA 
does not induce CL mRNA in mammalian ras transformed cell 
lines EJ/vHa-ras or EJ-ras. 
RNA transcription rate (run-on) assays were carried 
out which shows that the differences in mRNA levels for CL 
and uPA with the different ras oncogenes are primarily due 
to differences in transcription rates of the genes rather 
than to differences in mRNA stability. 
Based on the observation that urokinase is at a high 
level and PMA inducible only in mammalian ras oncogene 
transformed NIH 3T3 cells while cathepsin L is at a high 
level and inducible only in the yeast ras transformed NIH 
3T3 cells, I explored the possible roles of uPA and CL in 
metastasis in these cell lines using oligonucleotide anti-
sense inhibitors. Three 21-mer oligonucleotides were 
selected based on published mRNA sequences for uPA and CL, 
the sequences were designated sense-uPA (control), anti 
-sense uPA, and anti-sense CL. I showed that the antisense 
0-oligonucleotide can significantly inhibit CL and uPA 
expressions in a transient manner. In both the EJ/vHa-ras 
Leu 
cell line and the RASl del cell lines, anti-sense uPA 
inhibited 45% of uPA activity up to 48 hours and anti-sense 
CL inhibited 35% of the CL enzymatic activities up to 24 
hours. Based on these results, we proceeded to nude mice 
experiments to test the selective involvements of CL and 
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urokinase in these cells lines. 
EJ/vHa-ras cells were treated in vitro with the 
oligonucleotides and injected into nude mice through their 
tail vein. The anti-sense uPA significantly decrease the 
metastatic potential of EJ/vHa-ras transformed cells 
compared to control (p < 0.001). However, no effect of anti-
d . Leu Leu uPA was observe with RASl del cells. RASl del cells 
treated with anti-sense CL showed a significantly decrease 
in experimental metastasis from the control group (P < 
0.01). No effect of anti-CL on experimental metastasis was 
observed on the EJ/vHa-ras cells. The nude mouse assay with 
Leu RASl del cells was repeated more once, the anti-sense CL 
group different significantly from sense-uPA group in this 
repeat (p < 0.05). 
The results demonstrated that high levels of uPA and 
CL proteases are separately induced by different ras 
oncogene transformations and uPA and CL may compensate for 
each other in these two different metastatic pathways. 
TWO pairs of cell lines isolated from human origins 
were also investigated. PC3-P and M were isolated from human 
prostate carcinoma (Kozlowski et al., 1984). A375-P and 
A375-SM were from a human melanoma (Kozlowski et al., 1984). 
Characterization by Fidler and co-worker showed that PC3-P 
and A375-P exhibited a low metastatic potential, and PC3-M 
and A375-SM have a higher metastatic potentials. I found 
that uPA and its inhibitor, plasminogen activator inhibitor 
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2 (PAI-2) are both induced with PMA in the P and M lines. 
However, a more dramatic change of PAI-2 mRNA is observed, 
whereas uPA mRNA levels do not vary as greatly. It appears 
that the DAG analog (PMA) promotes the P cells to be less 
metastatic by inducing more PAI-2 rather than inducing the M 
line to be more metastatic by increasing uPA. 
A Western blot was utilized to confirm the induction 
of PAI-2 at the protein level. Without PMA treatment, there 
is no PAI-2 observed by Western blot. After PMA induction, 
PAI-2 protein is observed with much higher levels in the 
PC3-P cells than in the PC3-M cells. 
Cycloheximide, a protein synthesis inhibitor, was 
utilized to study uPA induction by PMA. Cycloheximide 
superinduced the uPA mRNA production triggered by PMA in 
PC3-P and PC3-M cells. 
I explored the differential response of PAI-2 in 
vivo by using conditioned medium from the organs cultures of 
nude mouse. PC3-P and M showed the increased mRNA production 
of PAI-2 under the stimulation of lung conditioned medium. 
There was a 5-fold greater stimulation of PAI-2 in the PC3-P 
line than PC3-M line. Conditioned media from other organs 
have no effect on PAI-2 mRNAs in these cell lines. 
Some conclusion can be drawn from this project: 
1. Transformation of different ras oncogenes can lead 
to dissimilar metastatic phenotypes shown by diverse 
protease expressions. Selective inhibition of UPA and CL 
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showed that uPA is critical in one phenotype and CL in the 
other phenotype. 
2. Signal factors in vivo may modulate tumor 
metastatic potential through regulation of the genes for 
protease inhibitors rather than through regulation of the 
gene for the proteases. Thus, in the PC3 cell lines, tumor 
metastatic potential may be primarily modulated through 
alteration of its PAI-2 activity. 
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